var title_f16_5_16464="Penile ulcer due to chancroid";
var content_f16_5_16464=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F76843&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F76843&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chancroid ulcer on penis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 348px; height: 266px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Penile ulcer due to chancroid which is accompanied by marked inguinal lymphadenitis",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_5_16464=[""].join("\n");
var outline_f16_5_16464=null;
var title_f16_5_16465="Echocardiogram Ebstein II";
var content_f16_5_16465=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F74450&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F74450&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    Echocardiogram in Ebstein anomaly",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 500px; height: 216px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Two dimensional 2 chamber view of the right ventricle (RV) and right atrium (RA) shows the anatomy of the displaced tricuspid valve leaflets (panel A); the sail-like anterior leaflet is attached to the tricuspid annulus (red arrow), the septal leaflet is rudimentary (yellow arrow), and the posterior leaflet is displaced apically (white arrow). A large amount of the RV is atrialized. The color Doppler echocardiogram (panel B) shows a moderate degree of tricuspid regurgitation (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_5_16465=[""].join("\n");
var outline_f16_5_16465=null;
var title_f16_5_16466="Patient information: Discoid lupus (The Basics)";
var content_f16_5_16466=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/87700\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/34/22054\">",
"         Discoid lupus erythematosus",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?21/42/22178\">",
"         Patient information: Lupus (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/49/36626\">",
"         Patient information: Lupus and kidney disease (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?7/30/7651\">",
"         Patient information: Lupus and pregnancy (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?28/35/29238\">",
"         Patient information: Systemic lupus erythematosus (SLE) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Discoid lupus (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H98023704\">",
"      <span class=\"h1\">",
"       What is discoid lupus?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Discoid lupus is a skin problem that causes raised red areas (called &ldquo;plaques&rdquo;) and scars on the skin (",
"      <a class=\"graphic graphic_picture graphicRef56910 \" href=\"UTD.htm?21/34/22054\">",
"       picture 1",
"      </a>",
"      ). Discoid lupus can happen anywhere on the skin but usually happens on the upper body. The most common places for discoid lupus are the face, neck, scalp, and ears.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H98023736\">",
"      <span class=\"h1\">",
"       What are the symptoms of discoid lupus?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The main symptom is red, scaly plaques. These plaques tend to slowly expand at the edges and then heal. When they heal, they leave behind discolored skin and sunken scars. Discoid lupus on the scalp can cause hair loss.",
"     </p>",
"     <p>",
"      Sometimes, people with discoid lupus also have lupus in other parts of the body. This is called &ldquo;systemic lupus.&rdquo; But most people with discoid lupus just have lupus in their skin.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H98023751\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you are being treated for discoid lupus, see your doctor or nurse if the condition does not improve with the medicine you were given or if it gets worse. Seeing your doctor or nurse right away is important because treating your discoid lupus early can help to prevent more skin discoloration and scars. You should also see your doctor or nurse if you notice new bumps or sores in places where you have discoid lupus.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H98023766\">",
"      <span class=\"h1\">",
"       Is there a test for discoid lupus?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If your doctor or nurse suspects you have discoid lupus, he or she can take a small sample of skin from 1 of your plaques and send it to the lab. There, another doctor will look at the types of cells that are present to learn whether you have discoid lupus.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H98023781\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. It&rsquo;s very important to protect your skin from the sun. Sun exposure tends to make the skin problems caused by discoid lupus worse. To protect yourself from the sun:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Stay out of the sun in the middle of the day (from 10 AM to 4 PM), when the sun&rsquo;s light is strongest",
"       </li>",
"       <li>",
"        Stay under a sun umbrella, tree, or other shady spot",
"       </li>",
"       <li>",
"        Wear sunscreen &ndash; Put sunscreen on all parts of the body that are not covered by clothes. Then reapply sunscreen every 2 to 3 hours, or after you sweat or swim. It&rsquo;s important to choose a sunscreen that:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Has an SPF of 30 or greater &ndash; SPF is a number that tells you how well a sunscreen protects the skin from UV light.",
"       </li>",
"       <li>",
"        Protects against 2 types of UV light, called &ldquo;UVA&rdquo; and &ldquo;UVB.&rdquo; (Sunscreens that offer both UVA and UVB protection are sometimes called &ldquo;broad spectrum.&rdquo;)",
"       </li>",
"       <li>",
"        Has not expired or is not more than 3 years old",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Wear a wide-brimmed hat, long-sleeved shirt, and long pants",
"       </li>",
"       <li>",
"        Do not use tanning beds",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you smoke, it&rsquo;s a good idea to quit. Discoid lupus seems to be more severe in people who smoke. Plus, smoking seems to make certain medicines for discoid lupus less effective.",
"     </p>",
"     <p>",
"      If you are bothered by the way discoid lupus looks on your skin, you can use special cosmetic products to make the skin changes less obvious. Both men and women can use these products. Examples are sold under the brand names Dermablend and Covermark. Other products can also be helpful.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H98023796\">",
"      <span class=\"h1\">",
"       How is discoid lupus treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatments include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Steroid medicines that come in ointments, creams, or gels &ndash; These steroid medicines reduce inflammation and help the skin heal. Examples include",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?8/16/8452?source=see_link\">",
"         fluocinonide",
"        </a>",
"        or",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?13/34/13860?source=see_link\">",
"         clobetasol",
"        </a>",
"        .",
"       </li>",
"       <li>",
"        Medicines called calcineurin inhibitors that come in ointments or creams. Examples include",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?3/7/3189?source=see_link\">",
"         pimecrolimus",
"        </a>",
"        (brand name: Elidel) and",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?37/24/38272?source=see_link\">",
"         tacrolimus",
"        </a>",
"        (brand name: Protopic).",
"       </li>",
"       <li>",
"        Steroid medicines that come in a shot, which is given directly into the portion of skin that is affected.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People who do not get better with the treatments mentioned above can get medicines that have been used to treat malaria. These medicines help with discoid lupus. Examples include",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?17/39/18037?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      (brand name: Plaquenil) and",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?1/35/1589?source=see_link\">",
"       chloroquine",
"      </a>",
"      (brand name: Aralen).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H98023811\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/42/22178?source=see_link\">",
"       Patient information: Lupus (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/30/7651?source=see_link\">",
"       Patient information: Lupus and pregnancy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/49/36626?source=see_link\">",
"       Patient information: Lupus and kidney disease (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/35/29238?source=see_link\">",
"       Patient information: Systemic lupus erythematosus (SLE) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?16/5/16466?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 87700 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-B09A38F648-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_5_16466=[""].join("\n");
var outline_f16_5_16466=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H98023704\">",
"      What is discoid lupus?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H98023736\">",
"      What are the symptoms of discoid lupus?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H98023751\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H98023766\">",
"      Is there a test for discoid lupus?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H98023781\">",
"      Is there anything I can do on my own to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H98023796\">",
"      How is discoid lupus treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H98023811\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/87700\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/34/22054\">",
"      Discoid lupus erythematosus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/42/22178?source=related_link\">",
"      Patient information: Lupus (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/49/36626?source=related_link\">",
"      Patient information: Lupus and kidney disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/30/7651?source=related_link\">",
"      Patient information: Lupus and pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/35/29238?source=related_link\">",
"      Patient information: Systemic lupus erythematosus (SLE) (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_5_16467="Palpable purpura on legs";
var content_f16_5_16467=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F56272&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F56272&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Palpable purpura",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Palpable purpura are present in this patient with cutaneous small vessel vasculitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from:",
"     <a href=\"file://www.visualdx.com\" target=\"_blank\">",
"      www.visualdx.com",
"     </a>",
"     . Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_5_16467=[""].join("\n");
var outline_f16_5_16467=null;
var title_f16_5_16468="Electrical alternans tutorial";
var content_f16_5_16468=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F51502&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F51502&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Electrical alternans",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 123px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Every other QRS complex has a reduced amplitude alternating with a higher amplitude.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_5_16468=[""].join("\n");
var outline_f16_5_16468=null;
var title_f16_5_16469="Value spot compression";
var content_f16_5_16469=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F78340&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F78340&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 515px\">",
"   <div class=\"ttl\">",
"    Value of spot compression",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 495px; height: 388px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    There is suggestion of a nodule (arrows) in the medial aspect of the breast on the CC view (Panel A). The borders, shape and size of the nodule are better evaluated with spot compression (Panel B).",
"    <div class=\"footnotes\">",
"     CC: craniocaudal.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_5_16469=[""].join("\n");
var outline_f16_5_16469=null;
var title_f16_5_16470="EP study tracings RF ablation atrial flutter";
var content_f16_5_16470=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F69946&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F69946&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 579px\">",
"   <div class=\"ttl\">",
"    Intracardiac and surface ECG recordings during electrophysiologic study and radiofrequency catheter ablation of typical atrial flutter",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 559px; height: 392px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Three surface ECG leads (I, aVF, V1) and intracardiac recordings from the high right atrium (HRA), a mapping catheter in the isthmus between the tricuspid valve and inferior vena cava (TV-IVC) (HBE1-2), eight recordings from a catheter extending from the lateral right atrial wall through the TV-IVC isthmus and into the ostium of the coronary sinus (CS15-1 to CS 1-2), and right ventricular apex (RVA3-4) in a patient with typical atrial flutter. The tip of the mapping catheter was initially positioned on the tricuspid annulus, and then dragged through the TV-IVC isthmus to the ostium of the IVC during RF application; atrial flutter terminated. Note that the atrial activation (A) blocks between CS7-8 and CS 5-6, which on fluoroscopy corresponded to the position of the mapping catheter.",
"    <div class=\"footnotes\">",
"     Fl: flutter waves; V: ventricular electrogram.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_5_16470=[""].join("\n");
var outline_f16_5_16470=null;
var title_f16_5_16471="Acute mastoiditis in children: Treatment and prevention";
var content_f16_5_16471=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acute mastoiditis in children: Treatment and prevention",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/5/16471/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/5/16471/contributors\">",
"     Ellen R Wald, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/5/16471/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/5/16471/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/5/16471/contributors\">",
"     Ellen M Friedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/5/16471/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/5/16471/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/5/16471/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute mastoiditis is the most common suppurative complication of acute otitis media (AOM) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16471/abstract/1\">",
"     1",
"    </a>",
"    ]. However, in more than one-half of cases, acute mastoiditis is the first evidence of AOM [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16471/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment and prevention of acute mastoiditis in children are discussed below. The clinical features and diagnosis of acute mastoiditis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/16/5385?source=see_link\">",
"     \"Acute mastoiditis in children: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    AOM is also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29642?source=see_link\">",
"     \"Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/35/8760?source=see_link\">",
"     \"Acute otitis media in children: Diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21514?source=see_link\">",
"     \"Acute otitis media in children: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Mastoiditis",
"      </strong>",
"      is a suppurative infection of the mastoid air cells.",
"     </li>",
"     <li>",
"      <strong>",
"       Acute mastoiditis",
"      </strong>",
"      is a suppurative infection of the mastoid air cells with symptoms of less than one month's duration [",
"      <a class=\"abstract\" href=\"UTD.htm?16/5/16471/abstract/5\">",
"       5",
"      </a>",
"      ]. Acute mastoiditis is subdivided according to the pathologic stage (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/16/5385?source=see_link&amp;anchor=H4#H4\">",
"       \"Acute mastoiditis in children: Clinical features and diagnosis\", section on 'Pathogenesis'",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/5/16471/abstract/1\">",
"       1",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Acute mastoiditis with periosteitis",
"      </strong>",
"      is defined by the presence of purulent material in the mastoid cavities.",
"     </li>",
"     <li>",
"      <strong>",
"       Coalescent mastoiditis",
"      </strong>",
"      (also called \"acute mastoid osteitis\") is defined by destruction of the thin bony septae between air cells. It may be followed by the formation of abscess cavities and the dissection of pus into adjacent areas.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Masked mastoiditis",
"      </strong>",
"      (also called &ldquo;subacute mastoiditis&rdquo;) refers to low-grade but persistent infection in the middle ear and mastoid with osteitis [",
"      <a class=\"abstract\" href=\"UTD.htm?16/5/16471/abstract/6\">",
"       6",
"      </a>",
"      ]. It occurs in patients with persistent middle-ear effusion or recurrent episodes of acute otitis media (AOM) without sufficient antimicrobial therapy.",
"     </li>",
"     <li>",
"      <strong>",
"       Chronic mastoiditis",
"      </strong>",
"      is a suppurative infection of the mastoid air cells of long-standing duration (months to years) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/5/16471/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bacterial species most often implicated in acute mastoiditis are",
"    <em>",
"     Streptococcus pneumoniae",
"    </em>",
"    (including multiply resistant",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    , particularly serotype 19A),",
"    <em>",
"     Streptococcus pyogenes",
"    </em>",
"    , and",
"    <em>",
"     Staphylococcus aureus",
"    </em>",
"    (including methicillin-resistant",
"    <em>",
"     S. aureus",
"    </em>",
"    ). Although",
"    <em>",
"     Pseudomonas aeruginosa",
"    </em>",
"    has been isolated frequently in some series [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16471/abstract/7,8\">",
"     7,8",
"    </a>",
"    ], exaggerated rates of recovery may occur if the sample for culture is taken from the external canal in patients with otorrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16471/abstract/7\">",
"     7",
"    </a>",
"    ].",
"    <em>",
"     P. aeruginosa",
"    </em>",
"    should only be considered as a potential pathogen in children with acute mastoiditis who have a history of recurrent acute otitis media and recent antibiotic use (especially if there is a perforation of the tympanic membrane). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/16/5385?source=see_link&amp;anchor=H5#H5\">",
"     \"Acute mastoiditis in children: Clinical features and diagnosis\", section on 'Microbiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     OVERVIEW OF MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of acute mastoiditis depends upon the stage and presence or absence and type of complications [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16471/abstract/1,9\">",
"     1,9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/16/5385?source=see_link&amp;anchor=H4#H4\">",
"     \"Acute mastoiditis in children: Clinical features and diagnosis\", section on 'Pathogenesis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/16/5385?source=see_link&amp;anchor=H10#H10\">",
"     \"Acute mastoiditis in children: Clinical features and diagnosis\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antimicrobial therapy and drainage of the middle ear and mastoid are the cornerstones of therapy for acute mastoiditis. However, treatment of acute mastoiditis in children has not been studied in randomized trials, and the approach to management varies from center to center [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16471/abstract/1\">",
"     1",
"    </a>",
"    ]. The recommendations below are based upon information from observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16471/abstract/3,7,10-15\">",
"     3,7,10-15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Referral indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of acute mastoiditis generally requires consultation with an otolaryngologist [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16471/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. Aspiration and drainage of the middle ear is necessary for diagnostic and therapeutic purposes. These procedures should be performed early in the disease process by an otolaryngologist.",
"   </p>",
"   <p>",
"    Consultation with otolaryngology for possible mastoidectomy is warranted for children with [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16471/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Postauricular fluctuance, mass, or swelling (suggesting subperiosteal abscess) (",
"      <a class=\"graphic graphic_picture graphicRef70910 \" href=\"UTD.htm?23/27/23999\">",
"       picture 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cervical fluctuance (ie, Bezold abscess)",
"     </li>",
"     <li>",
"      Imaging studies with evidence of rim-enhancing fluid collection, mastoid air cell coalescence, cortical bone erosion, or intracranial involvement",
"     </li>",
"     <li>",
"      High-spiking \"picket-fence\" fever (may indicate sigmoid sinus thrombophlebitis [",
"      <a class=\"abstract\" href=\"UTD.htm?16/5/16471/abstract/16\">",
"       16",
"      </a>",
"      ]); consultation with neurosurgery is also indicated",
"     </li>",
"     <li>",
"      Neurologic signs (eg, facial weakness, meningeal signs, focal deficits, altered level of consciousness, seizures); consultation with neurosurgery is also indicated",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Uncomplicated disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest that uncomplicated acute mastoiditis (acute mastoiditis with periosteitis or coalescent mastoiditis) and masked mastoiditis without intracranial complications be treated with intravenous antimicrobial therapy and myringotomy with or without placement of a tympanostomy tube [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16471/abstract/1,9,15,17,18\">",
"     1,9,15,17,18",
"    </a>",
"    ]. Acute mastoiditis with periosteitis (no postauricular",
"    <span class=\"nowrap\">",
"     mass/fluctuance,",
"    </span>",
"    no evidence of osteitis on imaging if imaging was obtained) may be treated in the outpatient setting (with parenteral antibiotics) if the infection is not severe [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16471/abstract/1,9,18\">",
"     1,9,18",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Antimicrobial therapy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H9\">",
"     'Drainage'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients should be monitored daily for clinical response. We suggest simple mastoidectomy if there is no clinical improvement (diminution of systemic and local findings) in 48 hours. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Treatment response'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Support for this approach is provided by retrospective observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16471/abstract/3,7,10-15\">",
"     3,7,10-15",
"    </a>",
"    ]. Prospective randomized trials are lacking.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Complicated disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute mastoiditis with extracranial or intracranial complications is usually treated with intravenous antibiotics, myringotomy with or without placement of a tympanostomy tube, and mastoidectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16471/abstract/1,13,17,19\">",
"     1,13,17,19",
"    </a>",
"    ]. However, we suggest that acute mastoiditis complicated by isolated facial nerve palsy be treated initially with intravenous antimicrobial therapy and myringotomy with or without placement of a tympanostomy tube [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16471/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Uncomplicated disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We suggest that children with suppurative complications of acute mastoiditis other than facial nerve palsy be treated with intravenous antimicrobial therapy, myringotomy with or without placement of a tympanostomy tube, and mastoidectomy. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Antimicrobial therapy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H9\">",
"     'Drainage'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Simple mastoidectomy in combination with antimicrobial therapy and tympanostomy tube placement is usually indicated as initial management when a subperiosteal abscess is noted at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16471/abstract/10,13\">",
"     10,13",
"    </a>",
"    ]. However, some experts favor postauricular aspiration as the initial procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16471/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional surgical interventions may be necessary for children with suppurative intratemporal or intracranial complications (eg, drainage of subperiosteal, subcutaneous, intratemporal, or intracranial collections, or thrombectomy) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16471/abstract/1,9\">",
"     1,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ANTIMICROBIAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of mastoiditis requires parenteral antimicrobial therapy. However, antimicrobial therapy is not necessarily sufficient, particularly in the later stages of the disease process, when it may be difficult to achieve adequate antibiotic levels in the bony tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16471/abstract/7\">",
"     7",
"    </a>",
"    ]. Antimicrobial therapy may fail to prevent the development of complications of acute mastoiditis. In a series of 223 patients, 8.5 percent developed complications during antimicrobial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16471/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Treatment response'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Empiric antimicrobial therapy for children with acute mastoiditis without a history of recurrent acute otitis media or recent antibiotic administration should provide coverage for the most frequent bacterial pathogens:",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    (including multiply resistant",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    ),",
"    <em>",
"     S. pyogenes",
"    </em>",
"    , and",
"    <em>",
"     S. aureus",
"    </em>",
"    (including methicillin-resistant",
"    <em>",
"     S. aureus",
"    </em>",
"    ). Antibiotics active against",
"    <em>",
"     P. aeruginosa",
"    </em>",
"    should be included in the empiric regimen if the child has a history of recurrent acute otitis media or has received antibiotics recently.",
"   </p>",
"   <p>",
"    In a child with either no previous history of acute otitis media or a history of a remote episode (ie, &gt;6 months before), empiric antimicrobial therapy with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    alone (60",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day divided every 6 hours with a maximum dose of 4",
"    <span class=\"nowrap\">",
"     gm/day)",
"    </span>",
"    will suffice as empiric treatment until microbiologic results are available (",
"    <a class=\"graphic graphic_table graphicRef61644 \" href=\"UTD.htm?13/35/13885\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    For children with a history of recurrent acute otitis media (most recent episode within six months) or recent antibiotic use, adequate coverage for gram-positive and gram-negative pathogens usually entails combination therapy (",
"    <a class=\"graphic graphic_table graphicRef61644 \" href=\"UTD.htm?13/35/13885\">",
"     table 1",
"    </a>",
"    ). Additional antimicrobial agents may be warranted in patients with specific complications (eg, brain abscess) or if Gram stain of aspirated material demonstrates an unexpected finding. Antimicrobial therapy is adjusted as necessary when results of culture and susceptibility tests are available.",
"   </p>",
"   <p>",
"    Intravenous treatment should be continued for 7 to 10 days, after which oral antimicrobial therapy can be substituted if the clinical response to treatment has been satisfactory. The total duration of antimicrobial therapy is four weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DRAINAGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of acute mastoiditis usually requires the drainage of pus from the middle ear",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mastoid cavity. Although there are reports of successful treatment without tympanocentesis or myringotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16471/abstract/3\">",
"     3",
"    </a>",
"    ], aspiration of middle-ear fluid is crucial in guiding definitive antimicrobial therapy. In addition, early drainage may interrupt the pathologic process and prevent complications [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16471/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/16/5385?source=see_link&amp;anchor=H4#H4\">",
"     \"Acute mastoiditis in children: Clinical features and diagnosis\", section on 'Pathogenesis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/16/5385?source=see_link&amp;anchor=H10#H10\">",
"     \"Acute mastoiditis in children: Clinical features and diagnosis\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The indications for the various drainage procedures (tympanocentesis, myringotomy, myringotomy with placement of tympanostomy tube, mastoidectomy) vary from center to center depending on the pathologic stage (acute mastoiditis with periosteitis versus coalescent mastoiditis) and presence or absence and type of complications [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16471/abstract/1,9,21\">",
"     1,9,21",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Overview of management'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tympanocentesis &ndash; At a minimum, tympanocentesis should be performed in all children with mastoiditis to obtain middle-ear fluid for culture and susceptibility testing [",
"      <a class=\"abstract\" href=\"UTD.htm?16/5/16471/abstract/1\">",
"       1",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/16/5385?source=see_link&amp;anchor=H18#H18\">",
"       \"Acute mastoiditis in children: Clinical features and diagnosis\", section on 'Microbiologic studies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Myringotomy &ndash; Myringotomy (surgical perforation of the tympanic membrane) permits drainage of the middle ear; it may be performed with or without placement of tympanostomy tubes. Myringotomy permits drainage of the mastoid if the aditus ad antrum is not blocked (",
"      <a class=\"graphic graphic_figure graphicRef74487 \" href=\"UTD.htm?16/51/17204\">",
"       figure 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?16/5/16471/abstract/1\">",
"       1",
"      </a>",
"      ]. A wide-field large myringotomy should be performed in children with acute mastoid osteitis to ensure adequate drainage [",
"      <a class=\"abstract\" href=\"UTD.htm?16/5/16471/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Tympanostomy tube placement &ndash; Tympanostomy tubes permit drainage over a longer duration than myringotomy alone [",
"      <a class=\"abstract\" href=\"UTD.htm?16/5/16471/abstract/1\">",
"       1",
"      </a>",
"      ]. Tympanostomy tube placement may be indicated for children who have chronic otitis media with effusion or a history of recurrent acute otitis media (AOM) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/5/16471/abstract/1\">",
"       1",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/56/3978?source=see_link\">",
"       \"Overview of tympanostomy tube placement and medical care of children with tympanostomy tubes\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42857?source=see_link&amp;anchor=H21#H21\">",
"       \"Acute otitis media in children: Prevention of recurrence\", section on 'Tympanostomy tubes'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Mastoidectomy &ndash; Mastoidectomy is the surgical removal of the mastoid cortical bone and underlying air cells. In simple mastoidectomy (also called cortical, complete, or canal-wall-up mastoidectomy), the posterior portion of the external auditory canal is preserved. In radical mastoidectomy (also called canal-wall-down mastoidectomy), the posterior portion of the external auditory canal is sacrificed.",
"      <br/>",
"      <br/>",
"      Simple mastoidectomy is performed to clean out the mastoid infection, open the aditus ad antrum, and provide external drainage [",
"      <a class=\"abstract\" href=\"UTD.htm?16/5/16471/abstract/1\">",
"       1",
"      </a>",
"      ]. Radical mastoidectomy is performed only when there is no clinical response to simple mastoidectomy, as evidenced by continued otorrhea or pain [",
"      <a class=\"abstract\" href=\"UTD.htm?16/5/16471/abstract/1\">",
"       1",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Indications for mastoidectomy may include [",
"      <a class=\"abstract\" href=\"UTD.htm?16/5/16471/abstract/1,5,21\">",
"       1,5,21",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Clinical findings consistent with subperiosteal abscess, such as postauricular fluctuance or mass (regardless of computed tomography [CT] findings)",
"     </li>",
"     <li>",
"      CT evidence of coalescent mastoiditis (regardless of other clinical features)",
"     </li>",
"     <li>",
"      Other suppurative complications of acute mastoiditis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/16/5385?source=see_link&amp;anchor=H10#H10\">",
"       \"Acute mastoiditis in children: Clinical features and diagnosis\", section on 'Complications'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Acute mastoiditis in a child with chronic suppurative otitis media or cholesteatoma",
"     </li>",
"     <li>",
"      Progression of postauricular swelling or fluctuance or persistence of fever, ear pain, or drainage despite parenteral antimicrobial therapy and",
"      <span class=\"nowrap\">",
"       tympanocentesis/myringotomy",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TREATMENT RESPONSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The response to treatment of acute mastoiditis is monitored through serial examination of the postauricular region, the external auditory canal, and the tympanic membrane for improvement or resolution of clinical findings [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16471/abstract/1,9\">",
"     1,9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fever",
"     </li>",
"     <li>",
"      Otalgia",
"     </li>",
"     <li>",
"      Postauricular tenderness, erythema, swelling, fluctuance, or mass",
"     </li>",
"     <li>",
"      Protrusion of the auricle",
"     </li>",
"     <li>",
"      Sagging or edema (narrowing) of the external auditory canal",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/16/5385?source=see_link&amp;anchor=H7#H7\">",
"     \"Acute mastoiditis in children: Clinical features and diagnosis\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with acute mastoiditis with periosteitis, periosteal involvement should resolve within 24 to 48 hours after",
"    <span class=\"nowrap\">",
"     tympanocentesis/myringotomy",
"    </span>",
"    and initiation of adequate antimicrobial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16471/abstract/1\">",
"     1",
"    </a>",
"    ]. Mastoidectomy is indicated in children who do not demonstrate adequate treatment response after 24 to 48 hours. Imaging of the temporal bone also may be indicated (to evaluate the development of intratemporal complications) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16471/abstract/1,5\">",
"     1,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similarly, patients with acute mastoid osteitis or complications who have been treated with intravenous antibiotics, myringotomy, and mastoidectomy should demonstrate clinical improvement within 24 to 48 hours of initiation of treatment. Radical mastoidectomy may be indicated for patients with persistent symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16471/abstract/1\">",
"     1",
"    </a>",
"    ]. Imaging of the temporal bone also may be indicated (to evaluate the development of intratemporal complications) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16471/abstract/1,5\">",
"     1,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The outcome of acute mastoiditis depends upon the extent of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16471/abstract/5,17\">",
"     5,17",
"    </a>",
"    ]. Most children with acute mastoiditis that is appropriately treated early in the course recover without complications or long-term sequelae (eg, hearing loss) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16471/abstract/10,17\">",
"     10,17",
"    </a>",
"    ]. Intracranial extension may be associated with permanent neurologic deficits or death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Audiology should be performed during the convalescence of children with acute mastoiditis to determine if they have hearing loss and, if so, whether it is conductive or sensory [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16471/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44344?source=see_link&amp;anchor=H9#H9\">",
"     \"Evaluation of hearing impairment in children\", section on 'Formal audiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children who develop intracranial complications of acute mastoiditis should be followed for the development of adverse neurologic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    otologic effects (eg, sensorineural hearing loss). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/49/26394?source=see_link\">",
"     \"Developmental-behavioral surveillance and screening in primary care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44344?source=see_link\">",
"     \"Evaluation of hearing impairment in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early, adequate treatment of acute otitis media (AOM) reduces the risk of developing mastoiditis but does not eliminate it altogether [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16471/abstract/4,7,22-24\">",
"     4,7,22-24",
"    </a>",
"    ]. In a retrospective cohort study, the rate of mastoiditis was 1.8 versus 3.8 per 10,000 episodes of AOM that were treated and not treated with antibiotics, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16471/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other possible preventive strategies include prevention of recurrent AOM and immunization with the pneumococcal conjugate vaccine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42857?source=see_link\">",
"     \"Acute otitis media in children: Prevention of recurrence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=see_link\">",
"     \"Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prompt treatment of acute mastoiditis and early evaluation of persistent ear drainage, ear pain, or AOM that is not responding to antimicrobial therapy may decrease the risk of developing complications of mastoiditis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16471/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute mastoiditis is a suppurative infection of the mastoid air cells with symptoms of less than one month's duration. It is subdivided according to the pathologic stage (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/16/5385?source=see_link&amp;anchor=H4#H4\">",
"       \"Acute mastoiditis in children: Clinical features and diagnosis\", section on 'Pathogenesis'",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Acute mastoiditis with periosteitis &ndash; purulent material in the mastoid cavities",
"     </li>",
"     <li>",
"      Coalescent mastoiditis &ndash; destruction of the thin bony septae between air cells",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The bacterial species most often implicated in acute mastoiditis are",
"      <em>",
"       Streptococcus pneumoniae",
"      </em>",
"      ,",
"      <em>",
"       Streptococcus pyogenes",
"      </em>",
"      , and",
"      <em>",
"       Staphylococcus aureus",
"      </em>",
"      .",
"      <em>",
"       P. aeruginosa",
"      </em>",
"      is a consideration for children with a history of recurrent acute otitis media or recent antibiotic use. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Consultation with specialty services (otolaryngology, neurosurgery as indicated) is warranted for children with clinical or radiographic evidence of complications or mastoid air cell coalescence on imaging studies. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Referral indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of acute mastoiditis depends upon the pathologic stage and presence or absence and type of complications. Antimicrobial therapy and drainage of the middle ear and mastoid are the cornerstones of therapy. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Overview of management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest that uncomplicated mastoiditis or masked mastoiditis without intracranial complications be treated with intravenous antimicrobial therapy and myringotomy with or without placement of a tympanostomy tube (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Uncomplicated disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that acute mastoiditis complicated by isolated facial nerve palsy be treated initially with intravenous antimicrobial therapy and myringotomy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Complicated disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that children with complications of acute mastoiditis other than facial nerve palsy be treated with intravenous antimicrobial therapy, myringotomy and mastoidectomy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Complicated disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Empiric antimicrobial therapy for children with acute mastoiditis without a history of recurrent acute otitis media or recent antibiotic administration should provide coverage for the most frequent bacterial pathogens:",
"      <em>",
"       S. pneumoniae",
"      </em>",
"      ,",
"      <em>",
"       S. pyogenes",
"      </em>",
"      , and",
"      <em>",
"       S. aureus",
"      </em>",
"      . Antibiotics active against",
"      <em>",
"       P. aeruginosa",
"      </em>",
"      should be included in the empiric regimen if the child has a history of recurrent acute otitis media or has received antibiotics recently. Suggested regimens are provided in the table (",
"      <a class=\"graphic graphic_table graphicRef61644 \" href=\"UTD.htm?13/35/13885\">",
"       table 1",
"      </a>",
"      ). Antimicrobial therapy is adjusted as necessary when results of culture and susceptibility tests are available. The total duration of antimicrobial therapy is four weeks. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Antimicrobial therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of acute mastoiditis requires the drainage of pus from the middle ear",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      mastoid cavity. The drainage procedure (tympanocentesis, myringotomy with or without placement of tympanostomy tube, mastoidectomy) varies depending upon the pathologic stage and the presence or absence and type of complications. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Drainage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most children with acute mastoiditis that is appropriately treated early in the course recover without complications or long-term sequelae (eg, hearing loss). Intracranial extension may be associated with permanent neurologic deficits or death. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Bluestone CD, Klein JO. Intratemporal complications and sequelae of otitis media. In: Pediatric otolaryngology, 4th ed, Bluestone CD, Casselbrant ML, Stool SE, et al (Eds), Saunders, Philadelphia 2003. p.687.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16471/abstract/2\">",
"      Bahadori RS, Schwartz RH, Ziai M. Acute mastoiditis in children: an increase in frequency in Northern Virginia. Pediatr Infect Dis J 2000; 19:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16471/abstract/3\">",
"      Geva A, Oestreicher-Kedem Y, Fishman G, et al. Conservative management of acute mastoiditis in children. Int J Pediatr Otorhinolaryngol 2008; 72:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16471/abstract/4\">",
"      Pang LH, Barakate MS, Havas TE. Mastoiditis in a paediatric population: a review of 11 years experience in management. Int J Pediatr Otorhinolaryngol 2009; 73:1520.",
"     </a>",
"    </li>",
"    <li>",
"     Lewis K, Shapiro NL, Cherry JD.. Mastoiditis. In: Textbook of Pediatric Infectious Diseases, 6th, Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL (Eds), Saunders, Philadelphia 2009. p.238.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16471/abstract/6\">",
"      Holt GR, Gates GA. Masked mastoiditis. Laryngoscope 1983; 93:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16471/abstract/7\">",
"      Luntz M, Brodsky A, Nusem S, et al. Acute mastoiditis--the antibiotic era: a multicenter study. Int J Pediatr Otorhinolaryngol 2001; 57:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16471/abstract/8\">",
"      Nussinovitch M, Yoeli R, Elishkevitz K, Varsano I. Acute mastoiditis in children: epidemiologic, clinical, microbiologic, and therapeutic aspects over past years. Clin Pediatr (Phila) 2004; 43:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16471/abstract/9\">",
"      Lin HW, Shargorodsky J, Gopen Q. Clinical strategies for the management of acute mastoiditis in the pediatric population. Clin Pediatr (Phila) 2010; 49:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16471/abstract/10\">",
"      Goldstein NA, Casselbrant ML, Bluestone CD, Kurs-Lasky M. Intratemporal complications of acute otitis media in infants and children. Otolaryngol Head Neck Surg 1998; 119:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16471/abstract/11\">",
"      Tamir S, Schwartz Y, Peleg U, et al. Acute mastoiditis in children: is computed tomography always necessary? Ann Otol Rhinol Laryngol 2009; 118:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16471/abstract/12\">",
"      Spratley J, Silveira H, Alvarez I, Pais-Clemente M. Acute mastoiditis in children: review of the current status. Int J Pediatr Otorhinolaryngol 2000; 56:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16471/abstract/13\">",
"      Cohen-Kerem R, Uri N, Rennert H, et al. Acute mastoiditis in children: is surgical treatment necessary? J Laryngol Otol 1999; 113:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16471/abstract/14\">",
"      Kvestad E, Kvaerner KJ, Mair IW. Acute mastoiditis: predictors for surgery. Int J Pediatr Otorhinolaryngol 2000; 52:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16471/abstract/15\">",
"      Bakhos D, Trijolet JP, Morini&egrave;re S, et al. Conservative management of acute mastoiditis in children. Arch Otolaryngol Head Neck Surg 2011; 137:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16471/abstract/16\">",
"      Davison SP, Facer GW, McGough PF, et al. Use of magnetic resonance imaging and magnetic resonance angiography in diagnosis of sigmoid sinus thrombosis. Ear Nose Throat J 1997; 76:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16471/abstract/17\">",
"      Anderson KJ. Mastoiditis. Pediatr Rev 2009; 30:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16471/abstract/18\">",
"      Niv A, Nash M, Peiser J, et al. Outpatient management of acute mastoiditis with periosteitis in children. Int J Pediatr Otorhinolaryngol 1998; 46:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16471/abstract/19\">",
"      Taylor MF, Berkowitz RG. Indications for mastoidectomy in acute mastoiditis in children. Ann Otol Rhinol Laryngol 2004; 113:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16471/abstract/20\">",
"      Lahav J, Handzel O, Gertler R, et al. Postauricular needle aspiration of subperiosteal abscess in acute mastoiditis. Ann Otol Rhinol Laryngol 2005; 114:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16471/abstract/21\">",
"      Zanetti D, Nassif N. Indications for surgery in acute mastoiditis and their complications in children. Int J Pediatr Otorhinolaryngol 2006; 70:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16471/abstract/22\">",
"      Thompson PL, Gilbert RE, Long PF, et al. Effect of antibiotics for otitis media on mastoiditis in children: a retrospective cohort study using the United kingdom general practice research database. Pediatrics 2009; 123:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16471/abstract/23\">",
"      van den Aardweg MT, Rovers MM, de Ru JA, et al. A systematic review of diagnostic criteria for acute mastoiditis in children. Otol Neurotol 2008; 29:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16471/abstract/24\">",
"      Mustafa A, Debry Ch, Wiorowski M, et al. Treatment of acute mastoiditis: report of 31 cases over a ten year period. Rev Laryngol Otol Rhinol (Bord) 2004; 125:165.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6036 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-71122602D8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_5_16471=[""].join("\n");
var outline_f16_5_16471=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      OVERVIEW OF MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Referral indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Uncomplicated disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Complicated disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ANTIMICROBIAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DRAINAGE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TREATMENT RESPONSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6036\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6036|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/51/17204\" title=\"figure 1\">",
"      Mastoid anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6036|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/27/23999\" title=\"picture 1\">",
"      Mastoiditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6036|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/35/13885\" title=\"table 1\">",
"      Mastoiditis Rx regimens",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/16/5385?source=related_link\">",
"      Acute mastoiditis in children: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/35/8760?source=related_link\">",
"      Acute otitis media in children: Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29642?source=related_link\">",
"      Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42857?source=related_link\">",
"      Acute otitis media in children: Prevention of recurrence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21514?source=related_link\">",
"      Acute otitis media in children: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/49/26394?source=related_link\">",
"      Developmental-behavioral surveillance and screening in primary care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44344?source=related_link\">",
"      Evaluation of hearing impairment in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/56/3978?source=related_link\">",
"      Overview of tympanostomy tube placement and medical care of children with tympanostomy tubes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=related_link\">",
"      Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_5_16472="Asbestosis";
var content_f16_5_16472=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Asbestosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/5/16472/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/5/16472/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/5/16472/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/5/16472/contributors\">",
"     Kevin R Flaherty, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/5/16472/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/5/16472/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/5/16472/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asbestosis specifically refers to the pneumoconiosis caused by inhalation of asbestos fibers. The disease is characterized by slowly progressive, diffuse pulmonary fibrosis. The spectrum of pulmonary disorders associated with asbestos exposure includes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Asbestosis",
"     </li>",
"     <li>",
"      Pleural disease (focal and diffuse benign pleural plaques)",
"     </li>",
"     <li>",
"      Malignancies (non-small cell and small cell carcinoma of the lung as well as malignant mesothelioma)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Asbestosis remains a significant clinical problem despite substantial reductions in occupational asbestos exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The pathophysiologic mechanisms and clinical manifestations of asbestosis will be reviewed here [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. The approach to the patient with suspected interstitial lung disease, and the 2004 American Thoracic Society statement on nonmalignant diseases related to asbestos, are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/20/22856?source=see_link\">",
"     \"Approach to the adult with interstitial lung disease: Clinical evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16681?source=see_link\">",
"     \"Approach to the adult with interstitial lung disease: Diagnostic testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The American Thoracic Society (ATS) statement on the diagnosis and management of nonmalignant asbestos-related diseases, as well as other ATS guidelines, can be accessed through the ATS web site at",
"    <a class=\"external\" href=\"file://www.thoracic.org/statements\">",
"     www.thoracic.org/statements",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ASBESTOS EXPOSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asbestos is the general term for a group of naturally occurring fibers composed of hydrated magnesium silicates. The tensile strength and chemical properties of asbestos are ideally suited for a variety of construction and insulating purposes.",
"   </p>",
"   <p>",
"    Asbestos fibers are divided into two categories based on their shape.",
"    <strong>",
"     Serpentine",
"    </strong>",
"    fibers, of which chrysotile is the only significant commercial variety, are long, curly strands, whereas",
"    <strong>",
"     amphibole",
"    </strong>",
"    fibers (crocidolite, amosite, tremolite, and others) are long, straight, rod-like structures. Chrysotile accounts for over 90 percent of the asbestos in commercial use in the United States and is generally considered less toxic than the amphibole fibers [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/4,5,7\">",
"     4,5,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because the use of asbestos has been ubiquitous, exposure can occur in a variety of occupational and non-occupational settings (",
"    <a class=\"graphic graphic_table graphicRef67902 \" href=\"UTD.htm?6/15/6396\">",
"     table 1",
"    </a>",
"    ). As examples, exposure to asbestos results from involvement with:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mining and milling of the fibers",
"     </li>",
"     <li>",
"      Industrial applications of asbestos (eg, work with textiles, cement, friction materials, insulation, shipbuilding)",
"     </li>",
"     <li>",
"      Nonoccupational exposure to airborne asbestos (eg, regular exposure to soiled work clothes brought home by an asbestos worker, renovation or demolition of asbestos-containing buildings, environmental exposure in the neighborhood of industrial sources, and natural environmental exposure to geological sources)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Environmental exposure to low levels of asbestos from naturally occurring sources or industrial emissions may increase the risk of malignant mesothelioma, but not asbestosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. The health risk to occupants of a building in which asbestos is in good repair and undisturbed is",
"    <strong>",
"     not",
"    </strong>",
"    considered significant [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asbestos-induced diseases are probably caused by the direct toxic effects of the fibers on pulmonary parenchymal cells as well as the release of various mediators (reactive oxygen species, proteases, cytokines, and growth factors) by inflammatory cells [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. Deleterious reactive oxygen and nitrogen free radicals may be formed either via reactions catalyzed by iron molecules within asbestos fibers or as a consequence of the activation of inflammatory cells. Free radicals can react with and damage a variety of cellular macromolecules and may disrupt DNA to give rise to malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Animal models suggest that inhaled asbestos fibers deposit at respiratory bronchiole and alveolar duct bifurcations [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. This triggers the accumulation of alveolar macrophages and the development of an inflammatory reaction that extends centrifugally into the terminal respiratory bronchioles and adjacent alveolar interstitium [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. The majority of fibers are removed from the lungs by mucociliary mechanisms, but some are taken up by alveolar macrophages and alveolar type I cells [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/16\">",
"     16",
"    </a>",
"    ]. Smoking increases the attack",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    progression rate of asbestosis, probably by interfering with the mucociliary clearance of inhaled fibers [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Amphibole fibers may be more toxic than chrysotile because their structure allows them to deposit more efficiently in the distal lung parenchyma and reduces their rate of clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In time, there is more diffuse pulmonary involvement characterized by loss of alveolar type I and II cells and by increases in the numbers of alveolar and interstitial macrophages, neutrophils, lymphocytes, and eosinophils. Fibroblast proliferation and collagen accumulation ultimately result [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/18,21,22\">",
"     18,21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients who develop asbestosis are asymptomatic for at least 20 to 30 years after the initial exposure; the latency period between exposure and symptoms is inversely proportional to the intensity of asbestos exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/4,5,15,23\">",
"     4,5,15,23",
"    </a>",
"    ]. In contrast, pleural disease is often present earlier. As an example, benign asbestos pleural effusions (BAPEs) usually occur within 15 years of first exposure to asbestos (range less than 1 year to up to 50 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/6,24,25\">",
"     6,24,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The earliest symptom of asbestosis is usually the insidious onset of breathlessness with exertion. Dyspnea commonly progresses inexorably even in the absence of further asbestos exposure. Cough, sputum production, and wheezing are unusual; if present, these symptoms tend to be a consequence of cigarette smoking rather than asbestos-induced lung disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;As asbestosis progresses, patients may develop bibasilar, fine end-inspiratory crackles (32 to 64 percent) and clubbing (32 to 42 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Cor pulmonale may ensue in advanced cases and may cause peripheral edema, jugular venous distension, hepatojugular reflux,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a right ventricular heave or gallop. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/17/36119?source=see_link\">",
"     \"Cor pulmonale\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory studies are generally nonspecific and not useful clinically. Antinuclear antibodies, rheumatoid factor, and an elevated erythrocyte sedimentation rate may be present but do not correlate with disease severity or activity [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pulmonary function tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The characteristic lung function abnormalities in patients with asbestosis include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Reduced lung volumes, particularly the vital capacity and total lung capacity",
"     </li>",
"     <li>",
"      Diminished single breath DLCO",
"     </li>",
"     <li>",
"      Decreased pulmonary compliance",
"     </li>",
"     <li>",
"      Absence of airflow obstruction by spirometry (normal ratio of the forced expiratory volume in one second to forced vital capacity)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The earliest physiologic abnormalities detected in asbestos-exposed patients are reductions in the DLCO and pulmonary compliance and the presence of exertional hypoxemia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/26,29\">",
"     26,29",
"    </a>",
"    ]. Although hypoxemia early in the course of disease occurs only with exercise, more advanced disease can be associated with hypoxemia at rest.",
"   </p>",
"   <p>",
"    Airways obstruction generally reflects concomitant exposure to cigarette smoke, but rarely occurs in the absence of tobacco exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/30\">",
"     30",
"    </a>",
"    ]. Airflow limitation in these patients may be due to inflammation of large airways resulting from asbestos deposition along the respiratory bronchioles and alveolar duct bifurcations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     IMAGING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Chest radiograph",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chest radiograph in patients with asbestosis usually reveals small bilateral parenchymal opacities with a multinodular or reticular pattern, often with associated pleural abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. These findings may be subtle. In one study, for example, 15 to 20 percent of individuals with histopathologic evidence of pulmonary fibrosis had no interstitial abnormalities on their chest radiographs [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The interstitial process typically begins in the lower lung zones and is associated with bilateral mid-lung zone plaques on the parietal pleura. In the early stages of asbestosis, combined interstitial and pleural involvement may cause a hazy, \"ground glass\" appearance to the chest radiograph that may blur the diaphragm and heart border, giving rise to the \"shaggy heart\" sign (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81236 \" href=\"UTD.htm?27/19/27967\">",
"     image 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/31\">",
"     31",
"    </a>",
"    ]. Honeycombing and upper lobe involvement develop in advanced stages of disease (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56976 \" href=\"UTD.htm?40/4/41039\">",
"     image 2",
"    </a>",
"    ). Hilar and mediastinal lymphadenopathy are not seen with asbestosis and should suggest the presence of another process.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Pleural disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pleural involvement is a hallmark of asbestos exposure, whereas it is unusual in other interstitial lung disorders. Approximately 50 percent of persons exposed to asbestos develop pleural plaques. The plaques preferentially involve the parietal pleura adjacent to ribs, are less extensive in the intercostal spaces, and only rarely occur on the visceral pleura. Plaques are most commonly found along the sixth through ninth ribs and along the diaphragm (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52721 \" href=\"UTD.htm?24/36/25157\">",
"     image 3",
"    </a>",
"    ). They are conspicuously absent in the region of the costophrenic sulci and at the lung apices. Calcifications are identified by chest radiography in 20 percent, on CT scanning in 50 percent, and at morphologic examination in 80 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/41/31382?source=see_link\">",
"     \"Imaging of pleural plaques, thickening, and tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pleural adhesions can cause atelectasis of a part of the peripheral lung, and this often takes on a rounded appearance on chest radiograph (ie, \"rounded atelectasis\") (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef82006 graphicRef78745 \" href=\"UTD.htm?12/2/12327\">",
"     image 4A-B",
"    </a>",
"    ). Rounded atelectasis can occur as a result of any type of pleural inflammation, but is most often associated with asbestos exposure (",
"    <a class=\"graphic graphic_picture graphicRef68171 \" href=\"UTD.htm?17/37/18002\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/34-36\">",
"     34-36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Benign asbestos pleural effusions (BAPEs) are usually small and unilateral and occur years before the onset of interstitial disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/24\">",
"     24",
"    </a>",
"    ]. The pleural fluid can be serous, serosanguinous, or overtly bloody. Approximately one-third of BAPEs have increased pleural eosinophils, sometimes up to 50 percent of the total nucleated cell count [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/37\">",
"     37",
"    </a>",
"    ]. Exclusion of pleural malignancy may require thoracoscopic evaluation. BAPEs typically resolve spontaneously over the course of several weeks, but may leave visible blunting of the costophrenic angle or thickening of the visceral pleura.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Computed tomographic scanning",
"    </span>",
"    &nbsp;&mdash;&nbsp;High resolution computed tomography (HRCT) is more sensitive than plain films in detecting parenchymal abnormalities in asbestos-exposed individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/38-42\">",
"     38-42",
"    </a>",
"    ]. Up to 30 percent of asbestos-exposed individuals demonstrate an abnormal HRCT in spite of a normal chest radiograph [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/43\">",
"     43",
"    </a>",
"    ]. However, HRCT may still appear normal or near normal in cases of histopathologically proven asbestosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The characteristic HRCT findings of asbestosis include (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77568 \" href=\"UTD.htm?6/15/6384\">",
"     image 5",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/40,41,43-46\">",
"     40,41,43-46",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Subpleural linear densities of varying length parallel to the pleura",
"     </li>",
"     <li>",
"      Basilar and dorsal lung parenchymal fibrosis, with peribronchiolar, intralobular, and interlobular septal fibrosis",
"     </li>",
"     <li>",
"      Coarse parenchymal bands (2 to 5 cm in length), often contiguous with the pleura",
"     </li>",
"     <li>",
"      Coarse honeycombing in advanced disease",
"     </li>",
"     <li>",
"      Pleural plaques, which, as noted above, help differentiate asbestos-induced parenchymal disease from other interstitial lung diseases",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The significance of abnormal HRCT scans in asymptomatic asbestos-exposed persons as well as the proper role of HRCT in detection of asbestos-induced lung disease need further study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Gallium lung scanning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asymptomatic subjects exposed to asbestos can have increased gallium uptake in the lung parenchyma suggestive of an active inflammatory or immune process [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/47\">",
"     47",
"    </a>",
"    ]. The degree of gallium uptake does not correlate with findings on the chest radiograph, pulmonary function tests, or bronchoalveolar lavage (BAL) cell profile [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/47\">",
"     47",
"    </a>",
"    ]. Therefore, the use of gallium scan in the evaluation of patients with asbestosis remains experimental.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microscopic examination of lung tissue is rarely needed to establish a diagnosis of asbestosis (",
"    <a class=\"graphic graphic_table graphicRef56557 \" href=\"UTD.htm?8/34/8748\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/1,21,29,48,49\">",
"     1,21,29,48,49",
"    </a>",
"    ]. The gross anatomic features of the disease include the presence of small, stiff lungs with fibrosis in the subpleural regions of the lower lobes. The adjacent visceral pleura may also be fibrotic and associated with parietal pleural plaques, while there usually is relative sparing of the central portions of the lung (",
"    <a class=\"graphic graphic_picture graphicRef66468 \" href=\"UTD.htm?22/11/22706\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The histopathologic diagnosis of asbestosis requires the presence of uncoated or coated asbestos fibers (asbestos bodies) in association with interstitial pulmonary fibrosis that is similar in appearance to usual interstitial pneumonitis (UIP) (",
"    <a class=\"graphic graphic_picture graphicRef61838 graphicRef81274 graphicRef70440 graphicRef59362 graphicRef50185 \" href=\"UTD.htm?42/44/43722\">",
"     picture 3A-E",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/29,48\">",
"     29,48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Asbestos bodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asbestos bodies are composed of transparent asbestos fibers surrounded by a coating of iron and protein. Such a coating may surround a number of other mineral particles, such as glass, talc, iron, or carbon; the resulting structures are generically called ferruginous bodies. Light microscopy does not allow accurate determination of the mineral at the core of a ferruginous body, and definitive identification may require scanning electron microscopy with energy dispersive x-ray analysis of lung specimens. Amphiboles form asbestos bodies more readily than do chrysotile fibers, in part due to the less efficient pulmonary clearance of amphiboles [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The quantity of asbestos fibers in the lungs (both coated and uncoated) is generally 10 to 20 fold higher in patients with asbestosis compared with unexposed individuals and correlates with the severity of fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/50\">",
"     50",
"    </a>",
"    ]. Quantification of asbestos bodies by light microscopy significantly underestimates the total lung fiber burden. The number of asbestos bodies in digested lung is generally 10 to 10,000 fold less than the total number of uncoated fibers determined by electron microscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Bronchoalveolar lavage",
"    </span>",
"    &nbsp;&mdash;&nbsp;The burden of parenchymal asbestos fibers is reflected by the number of such fibers in sputum and bronchoalveolar lavage (BAL) fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Increased numbers of asbestos bodies are found in sputum and BAL fluid of asbestos workers with asbestosis compared with asbestos workers with a normal chest radiograph [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Greater than one asbestos",
"    <span class=\"nowrap\">",
"     body/mL",
"    </span>",
"    of BAL fluid correlates with more than 1000 asbestos",
"    <span class=\"nowrap\">",
"     bodies/gram",
"    </span>",
"    of lung tissue in patients with suspected asbestos-related disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/53\">",
"     53",
"    </a>",
"    ]; such levels are associated with significant exposure.",
"   </p>",
"   <p>",
"    Unfortunately, the clinical utility of quantifying asbestos bodies in BAL fluid and tissues is limited. Interpretation of the results is difficult because of marked interpatient variation and the fact that a significant number of asbestos fibers may be present in exposed individuals without disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/50,54\">",
"     50,54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three key findings that support the diagnosis of asbestosis (",
"    <a class=\"graphic graphic_table graphicRef61308 graphicRef71021 \" href=\"UTD.htm?43/17/44317\">",
"     table 3A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A reliable history of exposure to asbestos with a proper latency period from the onset of exposure to the time of presentation,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      presence of markers of exposure (eg, pleural plaques, which are virtually pathognomonic of previous exposure, or recovery of sufficient quantities of asbestos",
"      <span class=\"nowrap\">",
"       fibers/bodies",
"      </span>",
"      in bronchoalveolar lavage or lung tissue) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Definite evidence of interstitial fibrosis, as manifested by one or more of the following: end-inspiratory crackles on chest examination; reduced lung volumes",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      DLCO; presence of typical chest radiograph or HRCT findings of interstitial lung disease; or histologic evidence of interstitial fibrosis.",
"     </li>",
"     <li>",
"      Absence of other causes of diffuse parenchymal lung disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is currently",
"    <strong>",
"     no",
"    </strong>",
"    specific treatment for asbestosis. There have been no prospective studies of patients with asbestosis utilizing antiinflammatory or immunosuppressive agents such as glucocorticoids or cytotoxic therapy. Whole lung lavage has been investigated as a means for removing retained dust in some pneumoconioses, but has not been applied to patients with asbestosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, management of patients with asbestosis should focus on preventive measures, including (",
"    <a class=\"graphic graphic_table graphicRef78800 \" href=\"UTD.htm?4/32/4620\">",
"     table 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Smoking cessation",
"     </li>",
"     <li>",
"      Early detection of physiologic and radiographic abnormalities",
"     </li>",
"     <li>",
"      Prevention of further airborne asbestos exposure",
"     </li>",
"     <li>",
"      Supplemental oxygen when there is resting hypoxemia or exercise-induced oxygen desaturation",
"     </li>",
"     <li>",
"      Prompt treatment of respiratory infections",
"     </li>",
"     <li>",
"      Pneumococcal and influenza vaccination",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two main complications of asbestos exposure are respiratory failure and malignancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Respiratory failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asbestosis is a slowly progressive process that culminates in respiratory failure in a minority of patients. Risk factors for progression of lung function abnormalities in asbestos-exposed individuals include [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/23,57\">",
"     23,57",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cumulative asbestos exposure",
"     </li>",
"     <li>",
"      Duration of exposure",
"     </li>",
"     <li>",
"      Fiber type (crocidolite exposure is associated with the most frequent progression)",
"     </li>",
"     <li>",
"      Symptoms of dyspnea",
"     </li>",
"     <li>",
"      Cigarette smoking",
"     </li>",
"     <li>",
"      Diffuse pleural thickening",
"     </li>",
"     <li>",
"      Honeycombing on HRCT",
"     </li>",
"     <li>",
"      Higher concentration of inflammatory cells (neutrophils and eosinophils) and fibronectin in bronchoalveolar lavage (BAL) fluid",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cigarette smoke may accelerate the progression of pulmonary fibrosis after asbestos exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/58\">",
"     58",
"    </a>",
"    ]. Although the mechanisms for this synergistic interaction are unknown, reactive oxygen species have been implicated as having a prominent role [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/4,5,59\">",
"     4,5,59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although some investigators have questioned the causal relationship between asbestosis and bronchogenic carcinoma, most studies have demonstrated a clear association between the two entities [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/42,60\">",
"     42,60",
"    </a>",
"    ]. As an example, a Dutch cohort study of 58,279 men, in which 524 cases of lung cancer developed, found that asbestos exposure was associated with a relative risk of lung cancer of 3.5 (95 percent CI 1.7 to 7.2) after adjustment for age, smoking habits, and intake of vitamin C,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"     beta-carotene",
"    </a>",
"    , and retinol [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The increased risk of lung cancer associated with asbestos is greatly magnified by coexisting exposure to tobacco smoke. In one report, for example, the risk of dying of lung cancer in asbestos workers increased 16-fold if they smoked more than 20 cigarettes per day and 9-fold if they smoked fewer than 20 cigarettes per day, compared to asbestos workers without a regular smoking history [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12298?source=see_link\">",
"     \"Cigarette smoking and other risk factors for lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of lung cancer associated with combined exposure to asbestos and cigarette smoke appears to be multiplicative. In the same report noted above [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/62\">",
"     62",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Asbestos exposure in the absence of a smoking history was associated with a 6-fold relative risk",
"     </li>",
"     <li>",
"      Cigarette smoking without a history of asbestos exposure was associated with an 11-fold increase in risk",
"     </li>",
"     <li>",
"      The relative risk for cigarette smokers with a history of asbestos exposure was 59",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For any given individual, the relative risk depends upon the magnitude of the exposure both to cigarette smoke and to asbestos. The type of asbestos fiber affects the risk of lung cancer as well; the risk appears to be considerably higher for workers exposed to amphibole fibers than for those exposed to chrysotile fibers [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/7,63\">",
"     7,63",
"    </a>",
"    ]. However, an analysis of 35-year prospective cohort data suggested a significant exposure&ndash;response relationship between exposure to chrysotile asbestos and increased risk for lung cancer mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Asbestos exposure increases the incidence of other neoplasms as well [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/4,5,65\">",
"     4,5,65",
"    </a>",
"    ]. Other malignancies that have been linked to asbestos include cancers of the larynx, oropharynx, kidney, esophagus, and biliary system [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16472/abstract/65\">",
"     65",
"    </a>",
"    ]. Asbestos is the",
"    <strong>",
"     only",
"    </strong>",
"    known risk factor for malignant mesothelioma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32552?source=see_link\">",
"     \"Clinical presentation, diagnosis, and staging of malignant pleural mesothelioma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/17/3347?source=see_link\">",
"       \"Patient information: Asbestos exposure (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Asbestosis specifically refers to the pneumoconiosis caused by inhalation of asbestos fibers. The disease is characterized by slowly progressive, diffuse pulmonary fibrosis. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Exposure to asbestos occurs during the mining and milling of the fibers, in industrial applications of asbestos (eg, work with cement, friction materials, insulation, shipbuilding), and in nonoccupational settings with airborne asbestos (eg, regular exposure to soiled work clothes brought home by an asbestos worker, renovation or demolition of asbestos-containing buildings). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Asbestos exposure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients who develop asbestosis are asymptomatic for at least 20 to 30 years after the initial exposure; the latency period between exposure and symptoms is inversely proportional to the intensity of asbestos exposure. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The earliest symptom of asbestosis is usually the insidious onset of breathlessness with exertion, which progresses inexorably even in the absence of further asbestos exposure. Cough, sputum production, and wheezing are unusual. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Typical high resolution computed tomography (HRCT) scan findings of asbestosis include: subpleural linear densities of varying length parallel to the pleura, basilar and dorsal lung parenchymal fibrosis, with peribronchiolar, intralobular, and interlobular septal fibrosis, coarse parenchymal bands (2 to 5 cm in length), often contiguous with the pleura, coarse honeycombing in advanced disease, and pleural plaques (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef77568 \" href=\"UTD.htm?6/15/6384\">",
"       image 5",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of asbestosis is based on a reliable history of exposure to asbestos with a proper latency period,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      presence of markers of exposure (eg, pleural plaques or recovery of sufficient quantities of asbestos",
"      <span class=\"nowrap\">",
"       fibers/bodies",
"      </span>",
"      in bronchoalveolar lavage or lung tissue); definite evidence of interstitial fibrosis (eg, end-inspiratory crackles, reduced lung volumes",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diffusing capacity, typical radiographic findings, or histologic evidence of interstitial fibrosis); and absence of other causes of diffuse parenchymal lung disease. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      No specific treatment has been identified for asbestosis. Management includes supportive care with an emphasis on smoking cessation, avoidance of further asbestos exposure, pneumococcal and influenza vaccination, and supplemental oxygen as needed to maintain adequate oxygenation. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/1\">",
"      American Thoracic Society. Diagnosis and initial management of nonmalignant diseases related to asbestos. Am J Respir Crit Care Med 2004; 170:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/2\">",
"      Centers for Disease Control and Prevention (CDC). Asbestosis-related years of potential life lost before age 65 years--United States, 1968-2005. MMWR Morb Mortal Wkly Rep 2008; 57:1321.",
"     </a>",
"    </li>",
"    <li>",
"     King TE Jr, Kamp DW, Panos RJ. Pneumoconioses, chronic interstitial pulmonary fibrosis, and bronchiolitis. In: Air Pollution and Lung Disease in Adults, Witorsch P, Spagnola SV (Eds), CRC Press, Boca Raton 1994. p.207.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/4\">",
"      Mossman BT, Gee JB. Asbestos-related diseases. N Engl J Med 1989; 320:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/5\">",
"      Mossman BT, Bignon J, Corn M, et al. Asbestos: scientific developments and implications for public policy. Science 1990; 247:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/6\">",
"      Wagner GR. Asbestosis and silicosis. Lancet 1997; 349:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/7\">",
"      Sichletidis L, Chloros D, Spyratos D, et al. Mortality from occupational exposure to relatively pure chrysotile: a 39-year study. Respiration 2009; 78:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/8\">",
"      Reid A, Berry G, de Klerk N, et al. Age and sex differences in malignant mesothelioma after residential exposure to blue asbestos (crocidolite). Chest 2007; 131:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/9\">",
"      Pan XL, Day HW, Wang W, et al. Residential proximity to naturally occurring asbestos and mesothelioma risk in California. Am J Respir Crit Care Med 2005; 172:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/10\">",
"      Kurumatani N, Kumagai S. Mapping the risk of mesothelioma due to neighborhood asbestos exposure. Am J Respir Crit Care Med 2008; 178:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/11\">",
"      Hansell A. Airborne environmental exposure to asbestos. Am J Respir Crit Care Med 2008; 178:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/12\">",
"      Rom WN, Travis WD, Brody AR. Cellular and molecular basis of the asbestos-related diseases. Am Rev Respir Dis 1991; 143:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/13\">",
"      Brody AR. Asbestos-induced lung disease. Environ Health Perspect 1993; 100:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/14\">",
"      Kamp DW, Weitzman SA. The molecular basis of asbestos induced lung injury. Thorax 1999; 54:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/15\">",
"      Mossman BT, Churg A. Mechanisms in the pathogenesis of asbestosis and silicosis. Am J Respir Crit Care Med 1998; 157:1666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/16\">",
"      Brody AR, Hill LH, Adkins B Jr, O'Connor RW. Chrysotile asbestos inhalation in rats: deposition pattern and reaction of alveolar epithelium and pulmonary macrophages. Am Rev Respir Dis 1981; 123:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/17\">",
"      Pinkerton KE, Pratt PC, Brody AR, Crapo JD. Fiber localization and its relationship to lung reaction in rats after chronic inhalation of chrysotile asbestos. Am J Pathol 1984; 117:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/18\">",
"      Chang LY, Overby LH, Brody AR, Crapo JD. Progressive lung cell reactions and extracellular matrix production after a brief exposure to asbestos. Am J Pathol 1988; 131:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/19\">",
"      Churg A, Stevens B. Enhanced retention of asbestos fibers in the airways of human smokers. Am J Respir Crit Care Med 1995; 151:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/20\">",
"      Blanc PD, Golden JA, Gamsu G, et al. Asbestos exposure-cigarette smoking interactions among shipyard workers. JAMA 1988; 259:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/21\">",
"      Hourihane DO, McCaughey WT. Pathological aspects of asbestosis. Postgrad Med J 1966; 42:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/22\">",
"      Lemaire I. Characterization of the bronchoalveolar cellular response in experimental asbestosis. Different reactions depending on the fibrogenic potential. Am Rev Respir Dis 1985; 131:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/23\">",
"      Becklake MR. Asbestos and other fiber-related diseases of the lungs and pleura. Distribution and determinants in exposed populations. Chest 1991; 100:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/24\">",
"      Epler GR, McLoud TC, Gaensler EA. Prevalence and incidence of benign asbestos pleural effusion in a working population. JAMA 1982; 247:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/25\">",
"      Paris C, Thierry S, Brochard P, et al. Pleural plaques and asbestosis: dose- and time-response relationships based on HRCT data. Eur Respir J 2009; 34:72.",
"     </a>",
"    </li>",
"    <li>",
"     Fraser RG, Pare JAP, Pare PD, et al. Pleuropulmonary disease caused by inhalation of inorganic dust (pneumoconiosis). In: Diagnosis of Diseases of the Chest, Fraser RG, Fraser RS Genereux GP (Eds), 1990. p.2346.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/27\">",
"      Murphy RL Jr, Gaensler EA, Holford SK, et al. Crackles in the early detection of asbestosis. Am Rev Respir Dis 1984; 129:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/28\">",
"      Turner-Warwick M, Parkes WR. Circulating rheumatoid and antinuclear factors in asbestos workers. Br Med J 1970; 3:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/29\">",
"      American Thoracic Society. Medical Section of the American Lung Association: The diagnosis of nonmalignant diseases related to asbestos. Am Rev Respir Dis 1986; 134:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/30\">",
"      Kilburn KH, Warshaw RH. Airways obstruction from asbestos exposure. Effects of asbestosis and smoking. Chest 1994; 106:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/31\">",
"      Freundlich, IM, Greening, RR. Asbestos and associated medical problems. Radiology 1967; 89:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/32\">",
"      Larson TC, Meyer CA, Kapil V, et al. Workers with Libby amphibole exposure: retrospective identification and progression of radiographic changes. Radiology 2010; 255:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/33\">",
"      Kipen HM, Lilis R, Suzuki Y, et al. Pulmonary fibrosis in asbestos insulation workers with lung cancer: a radiological and histopathological evaluation. Br J Ind Med 1987; 44:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/34\">",
"      Mintzer RA, Cugell DW. The association of asbestos-induced pleural disease and rounded atelectasis. Chest 1982; 81:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/35\">",
"      Hillerdal G. Rounded atelectasis. Clinical experience with 74 patients. Chest 1989; 95:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/36\">",
"      Voisin C, Fisekci F, Voisin-Saltiel S, et al. Asbestos-related rounded atelectasis. Radiologic and mineralogic data in 23 cases. Chest 1995; 107:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/37\">",
"      Mattson SB. Monosymptomatic exudative pleurisy in persons exposed to asbestos dust. Scand J Respir Dis 1975; 56:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/38\">",
"      Sette A, Neder JA, Nery LE, et al. Thin-section CT abnormalities and pulmonary gas exchange impairment in workers exposed to asbestos. Radiology 2004; 232:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/39\">",
"      Aberle DR, Gamsu G, Ray CS. High-resolution CT of benign asbestos-related diseases: clinical and radiographic correlation. AJR Am J Roentgenol 1988; 151:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/40\">",
"      Staples CA, Gamsu G, Ray CS, Webb WR. High resolution computed tomography and lung function in asbestos-exposed workers with normal chest radiographs. Am Rev Respir Dis 1989; 139:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/41\">",
"      M&uuml;ller NL, Miller RR. Computed tomography of chronic diffuse infiltrative lung disease. Part 1. Am Rev Respir Dis 1990; 142:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/42\">",
"      Banks DE, Shi R, McLarty J, et al. American College of Chest Physicians consensus statement on the respiratory health effects of asbestos. Results of a Delphi study. Chest 2009; 135:1619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/43\">",
"      Gamsu G, Salmon CJ, Warnock ML, Blanc PD. CT quantification of interstitial fibrosis in patients with asbestosis: a comparison of two methods. AJR Am J Roentgenol 1995; 164:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/44\">",
"      Aberle DR, Gamsu G, Ray CS, Feuerstein IM. Asbestos-related pleural and parenchymal fibrosis: detection with high-resolution CT. Radiology 1988; 166:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/45\">",
"      Aberle DR, Balmes JR. Computed tomography of asbestos-related pulmonary parenchymal and pleural diseases. Clin Chest Med 1991; 12:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/46\">",
"      M&uuml;ller NL, Miller RR. Computed tomography of chronic diffuse infiltrative lung disease. Part 2. Am Rev Respir Dis 1990; 142:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/47\">",
"      Delclos GL, Flitcraft DG, Brousseau KP, et al. Bronchoalveolar lavage analysis, gallium-67 lung scanning and soluble interleukin-2 receptor levels in asbestos exposure. Environ Res 1989; 48:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/48\">",
"      Craighead JE, Abraham JL, Churg A, et al. The pathology of asbestos-associated diseases of the lungs and pleural cavities: diagnostic criteria and proposed grading schema. Report of the Pneumoconiosis Committee of the College of American Pathologists and the National Institute for Occupational Safety and Health. Arch Pathol Lab Med 1982; 106:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/49\">",
"      A physician's guide to asbestos-related diseases. Council on Scientific Affairs. JAMA 1984; 252:2593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/50\">",
"      Roggli VL. Human disease consequences of fiber exposures: a review of human lung pathology and fiber burden data. Environ Health Perspect 1990; 88:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/51\">",
"      Teschler H, Thompson AB, Dollenkamp R, et al. Relevance of asbestos bodies in sputum. Eur Respir J 1996; 9:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/52\">",
"      De Vuyst P, Jedwab J, Dumortier P, et al. Asbestos bodies in bronchoalveolar lavage. Am Rev Respir Dis 1982; 126:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/53\">",
"      Sebastien P, Armstrong B, Monchaux G, Bignon J. Asbestos bodies in bronchoalveolar lavage fluid and in lung parenchyma. Am Rev Respir Dis 1988; 137:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/54\">",
"      Karjalainen A, Piipari R, M&auml;ntyl&auml; T, et al. Asbestos bodies in bronchoalveolar lavage in relation to asbestos bodies and asbestos fibres in lung parenchyma. Eur Respir J 1996; 9:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/55\">",
"      Mizell KN, Morris CG, Carter JE. Antemortem diagnosis of asbestosis by screening chest radiograph correlated with postmortem histologic features of asbestosis: a study of 273 cases. J Occup Med Toxicol 2009; 4:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/56\">",
"      Wilt JL, Banks DE, Weissman DN, et al. Reduction of lung dust burden in pneumoconiosis by whole-lung lavage. J Occup Environ Med 1996; 38:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/57\">",
"      Schwartz DA, Davis CS, Merchant JA, et al. Longitudinal changes in lung function among asbestos-exposed workers. Am J Respir Crit Care Med 1994; 150:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/58\">",
"      Tron V, Wright JL, Harrison N, et al. Cigarette smoke makes airway and early parenchymal asbestos-induced lung disease worse in the guinea pig. Am Rev Respir Dis 1987; 136:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/59\">",
"      Kamp DW, Graceffa P, Pryor WA, Weitzman SA. The role of free radicals in asbestos-induced diseases. Free Radic Biol Med 1992; 12:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/60\">",
"      Warnock ML, Isenberg W. Asbestos burden and the pathology of lung cancer. Chest 1986; 89:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/61\">",
"      van Loon AJ, Kant IJ, Swaen GM, et al. Occupational exposure to carcinogens and risk of lung cancer: results from The Netherlands cohort study. Occup Environ Med 1997; 54:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/62\">",
"      Hammond EC, Selikoff IJ, Seidman H. Asbestos exposure, cigarette smoking and death rates. Ann N Y Acad Sci 1979; 330:473.",
"     </a>",
"    </li>",
"    <li>",
"     Hughes, JM, Weill, H. Asbestos and man-made fibers. In: Samet, JM, (Ed), Epidemiology of Lung Cancer, Marcel Dekker, New York, 1994, p. 185.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/64\">",
"      Deng Q, Wang X, Wang M, Lan Y. Exposure-response relationship between chrysotile exposure and mortality from lung cancer and asbestosis. Occup Environ Med 2012; 69:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16472/abstract/65\">",
"      Selikoff IJ. Historical developments and perspectives in inorganic fiber toxicity in man. Environ Health Perspect 1990; 88:269.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4307 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.167.4.114-2B3BC00349-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_5_16472=[""].join("\n");
var outline_f16_5_16472=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ASBESTOS EXPOSURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pulmonary function tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      IMAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Chest radiograph",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Pleural disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Computed tomographic scanning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Gallium lung scanning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Asbestos bodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Bronchoalveolar lavage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Respiratory failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4307\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4307|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?27/19/27967\" title=\"diagnostic image 1\">",
"      Early asbestosis CXR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?40/4/41039\" title=\"diagnostic image 2\">",
"      Advanced asbestosis CXR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?24/36/25157\" title=\"diagnostic image 3\">",
"      Pleural plaques asbestos PA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?12/3/12341\" title=\"diagnostic image 4A\">",
"      Rounded atelectasis PA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/20/2383\" title=\"diagnostic image 4B\">",
"      Rounded atelectasis CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?6/15/6384\" title=\"diagnostic image 5\">",
"      Asbestosis CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4307|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/37/18002\" title=\"picture 1\">",
"      Rounded atelectasis Low",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/11/22706\" title=\"picture 2\">",
"      Asbestosis lung gross",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/57/1936\" title=\"picture 3A\">",
"      Asbestos body Photomicrograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/45/23256\" title=\"picture 3B\">",
"      Asbestosis Photomicrograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/50/13090\" title=\"picture 3C\">",
"      Asbestosis histology A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/44/18117\" title=\"picture 3D\">",
"      Grade III asbestosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/27/26037\" title=\"picture 3E\">",
"      Grade IV asbestosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4307|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/15/6396\" title=\"table 1\">",
"      Asbestosis and job risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/34/8748\" title=\"table 2\">",
"      Asbestosis histologic grades",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/60/34764\" title=\"table 3A\">",
"      Dx asbestos disease A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/37/38492\" title=\"table 3B\">",
"      Dx asbestos disease B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/32/4620\" title=\"table 4\">",
"      Management of asbestosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/20/22856?source=related_link\">",
"      Approach to the adult with interstitial lung disease: Clinical evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16681?source=related_link\">",
"      Approach to the adult with interstitial lung disease: Diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12298?source=related_link\">",
"      Cigarette smoking and other risk factors for lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32552?source=related_link\">",
"      Clinical presentation, diagnosis, and staging of malignant pleural mesothelioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/17/36119?source=related_link\">",
"      Cor pulmonale",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/41/31382?source=related_link\">",
"      Imaging of pleural plaques, thickening, and tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/17/3347?source=related_link\">",
"      Patient information: Asbestos exposure (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_5_16473="Epidemiology, prevention, and control of malaria in endemic areas";
var content_f16_5_16473=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, prevention, and control of malaria in endemic areas",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/5/16473/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/5/16473/contributors\">",
"     Joel G Breman, MD, DTPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/5/16473/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/5/16473/contributors\">",
"     Johanna Daily, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/5/16473/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/5/16473/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/5/16473/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malaria is endemic throughout most of the tropics. Of the approximately three billion people living in 106 countries who are exposed, approximately 243 million will develop symptomatic malaria annually [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/1\">",
"     1",
"    </a>",
"    ]. Most of these are attributable to P. falciparum, but P. vivax and P. knowlesi can also cause severe disease. Malaria deaths peaked at 1.82 million in 2004 and fell to 1.24 million in 2010 (714,000 children &lt;5 years and 524,000 individuals &ge;5 years); over 80 percent of the deaths occur in sub-Saharan Africa [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Important components for reducing the burden of malaria morbidity and mortality include more sensitive diagnostic tools, effective use of antimalarial drugs, and improved personal protection and mosquito control. The approach to elimination or control of malaria includes these basics, along with improvements in tracking of human illness and parasite surveillance, and effective resource delivery.",
"   </p>",
"   <p>",
"    Issues related to epidemiology of malaria, including definitions and strategies for control, will be reviewed. Other related topics are discussed in detail separately. (See related topics).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malaria is transmitted via the bite of a female Anopheles spp mosquito, which occurs mainly between dusk and dawn. Other comparatively rare mechanisms for transmission include: congenitally-acquired disease, blood transfusion, sharing of contaminated needles, and organ transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Malaria occurs throughout most of the tropical regions of the world, with P. falciparum causing the largest burden of disease, followed by P. vivax (",
"    <a class=\"graphic graphic_figure graphicRef72797 \" href=\"UTD.htm?38/32/39430\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. P. falciparum predominates in Africa, New Guinea, and Hispaniola (Haiti and the Dominican Republic); P. vivax is more common in the Americas and the western Pacific. The prevalence of these two species is approximately equal in the Indian subcontinent, eastern Asia, and Oceania (",
"    <a class=\"graphic graphic_table graphicRef59290 \" href=\"UTD.htm?31/50/32556\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. P. malariae is uncommon and is found in most endemic areas, especially in sub-Saharan Africa. P. ovale, even less common, is relatively unusual outside of Africa and, where it is found, comprises &lt;1 percent of isolates. P. knowlesi, similar morphologically to P. malariae, has been identified by molecular methods in patients in Malaysia, the Philippines, Thailand, and Myanmar [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/9\">",
"     9",
"    </a>",
"    ]; this species has not yet been proven to be transmitted from humans to mosquitoes (ie, a monkey reservoir may be required to infect mosquitoes).",
"   </p>",
"   <p>",
"    The epidemiology of malaria may vary considerably even within relatively small geographic areas. Endemicity traditionally has been defined in terms of parasitemia rates or palpable spleen rates in children two to nine years of age as hypoendemic (&le;10 percent), mesoendemic (11 to 50 percent), hyperendemic (51 to 74 percent), and holoendemic (&ge;75 percent). In holo- and hyperendemic areas (eg, certain regions of tropical Africa or coastal New Guinea where there is intense P. falciparum transmission), people may receive more than one infectious mosquito bite per day, and are infected repeatedly throughout their lives. In such settings with intense perennial transmission, morbidity and mortality due to malaria during childhood are considerable.",
"   </p>",
"   <p>",
"    The entomologic inoculation rate (EIR; the number of infectious female anopheline bites per person per year) is a term used to indicate transmission intensity. While there are seasonal and geographic differences, an EIR of",
"    <span class=\"nowrap\">",
"     &lt;10/year",
"    </span>",
"    is low transmission, 10 to",
"    <span class=\"nowrap\">",
"     49/year",
"    </span>",
"    is intermediate, and",
"    <span class=\"nowrap\">",
"     &ge;50/year",
"    </span>",
"    is a high transmission area. In general, the higher the EIR, the greater the burden of malaria, particularly on young children [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Constant, year-round infection is termed stable transmission, generally occurring in areas with EIRs of",
"    <span class=\"nowrap\">",
"     &ge;50/year;",
"    </span>",
"    in such areas, most malaria infections in adults are asymptomatic. In areas where transmission is low, highly seasonal, or focal, full protective immunity is not acquired, and symptomatic disease occurs at all ages. Malaria behaves like an epidemic disease in some areas, particularly those with seasonal unstable malaria such as northern India (Rajasthan), Sri Lanka, Afghanistan, Iraq, Turkey, Ethiopia, Eritrea, Burundi, southern Africa (Botswana, Mozambique, Namibia, South Africa, Swaziland, Zimbabwe), Madagascar, and southeastern Europe (Azerbaijan, Tajikistan). An epidemic can develop when there are changes in environmental, economic, or social conditions, such as heavy rains following drought or migrations (usually of refugees or workers) from a non-malarious region to an area of high transmission; a breakdown in malaria control and prevention services can intensify epidemic conditions. This situation usually results in considerable morbidity and mortality among all age groups [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The principal determinants of the epidemiology of malaria are the number (density), the human-biting habits (indoors or outdoors), and the longevity of the female anopheline vectors. More specifically, the transmission of malaria is directly proportional to the density of the vector, the square of the number of human bites per day per mosquito, and the tenth power of the probability of the mosquito's survival for one day [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Mosquito longevity is particularly important, because the portion of the parasite's life cycle that takes place within the mosquito (sporogony) -- from gametocyte ingestion to subsequent inoculation -- lasts for 8 to 30 days, depending on the species of Plasmodium and ambient temperature; thus, to transmit malaria, the mosquito must survive for &gt;10 days. The most effective mosquito vectors of malaria are those such as An. gambiae in Africa, which are long-lived, occur in high densities in tropical climates, breed readily, rest and bite within dwellings, and bite humans in preference to other animals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23968136\">",
"    <span class=\"h2\">",
"     Chloroquine susceptibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;The spread of drug-resistant P. falciparum malaria has been a major impediment to malaria control. The distribution and approach to therapy for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    resistant malaria are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/41/25241?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of uncomplicated falciparum malaria\", section on 'Chloroquine resistant malaria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a region of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    resistance in Malawi, return of chloroquine-susceptible malaria was demonstrated following abandonment of chloroquine use [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/14\">",
"     14",
"    </a>",
"    ]. These chloroquine-susceptible parasites likely represent a reexpansion of the susceptible parasites that survived in the population despite widespread drug pressure in the region.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;To consider interventions for malaria control, it is important to define the goals of control, elimination, and eradication. Control is reduction of disease incidence and prevalence to levels that do not pose a threat to public health or that are acceptable to a community. The Millennium Development Goals (MDGs) have quantified malaria control as reduction of malaria morbidity and mortality by 75 percent by 2015 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/12,15,16\">",
"     12,15,16",
"    </a>",
"    ]. Elimination is reduction of incidence and transmission to zero in humans in a defined geographic area. Eradication is global elimination of human disease. In all instances, a surveillance system that could detect, respond to, and report malaria cases and infections promptly is essential.",
"   </p>",
"   <p>",
"    One problem with the MDGs is that baseline epidemiological information for malaria (and other diseases) is woefully incomplete in most endemic countries. Following successful elimination and eradication, ongoing rigorous surveillance is needed to identify imported cases, which must be detected, treated, and contained promptly to prevent reestablishment of endemic infection. Because there are no non-human reservoirs for the human plasmodia, malaria is considered by many to be a candidate for eradication.",
"   </p>",
"   <p>",
"    Clinical diagnosis alone has been used in most endemic African areas for recording malaria cases, contributing to imprecisions. Training and supervision of clinicians in proper diagnosis of presumed malaria remain the most important keys to effective management and surveillance [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/17\">",
"     17",
"    </a>",
"    ]. Microscopic confirmation of malaria, the historic \"gold standard,\" is frequently delayed and inaccurate; hence, the rapid diagnostic test (RDT) is being used with increasing frequency. Advantages of RDTs include improved diagnosis, rapidity, and more rational use of antimalarial drugs. Diagnosis of malaria is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10248?source=see_link\">",
"     \"Diagnosis of malaria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With the October 2007 Bill and Melinda Gates challenge to the world community to eradicate malaria, there is increasing enthusiasm to reassess older control methods and develop and evaluate new ones through research. The approach to malaria eradication proposed by the WHO includes the preparatory, attack, consolidation, and maintenance phases (",
"    <a class=\"graphic graphic_figure graphicRef79347 \" href=\"UTD.htm?25/7/25726\">",
"     figure 2",
"    </a>",
"    ). Progression between these phases depends on reducing the incidence of parasitemia in the population, which requires an understanding of the intrinsic and extrinsic factors of malaria transmission. Intrinsic factors include the relationships between human, parasite, and mosquito; extrinsic factors include the environment, and socio-economic milieu, and control initiatives [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/18\">",
"     18",
"    </a>",
"    ]. The most important epidemiological criterion for moving from the attack to the consolidation phase of malaria eradication (in which surveillance is the key) is annual incidence of &lt;0.1",
"    <span class=\"nowrap\">",
"     infections/1000",
"    </span>",
"    persons (1 case per 10,000 population) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     STRATEGIES FOR CONTROL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Strategies to disrupt malaria transmission include effective deployment of antimalarial drugs, personal mosquito protection, mosquito vector control, and research (including vaccine development) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/12\">",
"     12",
"    </a>",
"    ]. Optimal malaria control (eg, leading to elimination) using these tools requires the following elements:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Effective human, parasitological, and entomological surveillance at health facilities and in communities",
"     </li>",
"     <li>",
"      An understanding of local Anopheline ecology (including breeding, biting, and resting habits)",
"     </li>",
"     <li>",
"      Administrative, managerial, supervisory, and operational capacity (including trained leaders and staff)",
"     </li>",
"     <li>",
"      An ongoing monitoring and evaluation system for deployment and use of drugs, long-lasting insecticidal nets (LLINs), indoor residual spraying (IRS) and environmental modifications",
"     </li>",
"     <li>",
"      Sustained high level, long-term national and international commitment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    WHO has divided 104 malarious countries into three groups: 25 countries that have recently eliminated malaria or with conditions amenable to elimination, 32 countries with unstable malaria amenable to control and elimination with current tools, and 47 countries with stable transmission and poor infrastructure (eg, requiring further infrastructure development before additional measures can be implemented) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/1,8\">",
"     1,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Stringent environmental management and \"integrated vector control\" (concurrent use of multiple approaches) will be required for eradication. Long-lasting insecticidal nets (LLINs) and indoor residual spraying (IRS) are strategic components for all three groups; these and other strategies are discussed in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Antimalarial drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of antimalarial drugs for treatment of acute illness is essential, although their effect on transmission and control of malaria in endemic areas is limited since most antimalarial drugs do not eliminate gametocytes.",
"   </p>",
"   <p>",
"    Issues related to use of gametocidal drugs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=see_link\">",
"     primaquine",
"    </a>",
"    for reduction of malaria transmission are discussed further separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/41/25241?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment of uncomplicated falciparum malaria\", section on 'Resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29018577\">",
"    <span class=\"h3\">",
"     Intermittent preventive treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intermittent preventive treatment (IPT) is effective for reducing the risk of malaria infection among pregnant women (IPTp) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/12,19\">",
"     12,19",
"    </a>",
"    ]. This issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20695?source=see_link\">",
"     \"Treatment and prevention of malaria in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intermittent preventive treatment in infants (IPTi) with slowly eliminated antimalarials appears to be effective for reducing episodes of malaria in infants, and does not appear to affect serologic response to routine vaccinations [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/20\">",
"     20",
"    </a>",
"    ]. We are in agreement with the World Health Organization (WHO) recommendation for coadministration of IPTi with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/37/34389?source=see_link\">",
"     sulfadoxine-pyrimethamine",
"    </a>",
"    (SP) to infants at the time of the DTP and measles vaccinations (second and third doses), in areas of sub-Saharan Africa with moderate to high malaria transmission and where malaria parasites are sensitive to these drugs.",
"   </p>",
"   <p>",
"    A pooled analysis of six trials evaluating use of SP administered to 7930 infants at the time of routine vaccination demonstrated protective efficacy of 30 percent for malaria prevention for about one month following each dose; no reduction in mortality was observed (although the trials were powered only to show large differences) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/21\">",
"     21",
"    </a>",
"    ]. In another trial including 2419 infants, administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"     mefloquine",
"    </a>",
"    at the time of routine immunization demonstrated protective efficacy (38 percent) against clinical malaria in infants aged 2 to 11 months [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/22\">",
"     22",
"    </a>",
"    ]. Such practice does not appear to affect serologic response to vaccines [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/20,23\">",
"     20,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The level of transmission intensity below which the risks exceed the benefits is uncertain. As resistance increases to SP and other antimalarial drugs, the efficacy of IPTi will decrease where these drugs are used [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/24\">",
"     24",
"    </a>",
"    ]. We are in agreement with the WHO, which recommends SP for IPTi in areas of moderate or intense malaria transmission, but not if the frequency of the",
"    <em>",
"     Pfdhps",
"    </em>",
"    +",
"    <em>",
"     Pfdhfr",
"    </em>",
"    quintuple mutants (molecular markers of parasite resistance to SP) is &ge;50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intermittent preventive treatment in children &lt;6 years (IPTc) has been shown to be effective in areas where malaria is seasonal; antimalarial drugs are administered to prevent malaria at regular intervals during the transmission season regardless of whether malaria symptoms are present. A review of seven trials including 12,589 participants noted that IPTc prevented 75 percent of malaria episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/26\">",
"     26",
"    </a>",
"    ]. The most studied regimen is amodiaquine plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/37/34389?source=see_link\">",
"     sulfadoxine-pyrimethamine",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Mosquito vector control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mosquito vector control methods reduce the mosquito population and include use of insecticide treated nets (ITNs), household insecticide indoor residual spraying (IRS), and larval control by environmental management. Genetic control methods remain an area of research. Since effective insecticides have become available for use against adult Anopheles, ITNs and IRS have become the most important measures for mosquito vector control.",
"   </p>",
"   <p>",
"    Requirements for effective sustained implementation of vector control include [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/27\">",
"     27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Continual monitoring for Anopheles resistance and cross resistance to the insecticides deployed",
"     </li>",
"     <li>",
"      Entomology expertise (including mosquito species identification and their biting and feeding habits) and vector control technology",
"     </li>",
"     <li>",
"      Close supervision and monitoring of the effect of the intervention on the entomological inoculation rates and on clinical and parasitological indices",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Insecticide treated nets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bed nets are a sensible physical barrier precaution against malaria-transmitting mosquitoes since the major malaria vectors bite during the night (for example, An. gambiae and An. funestus) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Addition of a chemical barrier in the form of pyrethroid treatment to bed nets provides protection, even if the net is torn.",
"   </p>",
"   <p>",
"    Pyrethroids are the major insecticides used routinely for bed net treatment. Newer long-lasting insecticidal nets (LLINs) are washproof pyrethroid impregnated nets; they may be used for about five years, after which they must be replaced because of wear (with holes) and a decreased pyrethroid content. Only LLINs should be deployed in control and elimination programs.",
"   </p>",
"   <p>",
"    Widespread community use of ITNs reduces the proportion of mosquitoes surviving long enough to transmit malaria; each attempt at a blood meal from an ITN-protected human results in a potentially lethal insecticide exposure for the mosquito [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/29\">",
"     29",
"    </a>",
"    ]. A study in the Gambia showed that community-wide ITN coverage can reduce malaria-attributable mortality by 30 percent and overall mortality in children by 37 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/30\">",
"     30",
"    </a>",
"    ]. Use of pyrethroid impregnated nets thus far does not appear to have toxicity for humans but further evaluation is warranted [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/31-33\">",
"     31-33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For high frequency of adherence to ITN use, health education in communities is essential for assuring correct installation, hours of use, and maintenance of the ITNs. Follow up of ITNs provided to a community in Tanzania several years earlier confirmed that individuals continued to use the nets, in part because of their additional impact on other nuisance insects such as bedbugs [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some have postulated that use of ITNs for reducing the burden of malaria may slow development of immunity to infection among children; this does not appear to be the case. After nearly four years of community ITN use in Tanzania, morbidity among very young children diminished, and morbidity among older children was comparable to aged-matched controls in villages without nets [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/29\">",
"     29",
"    </a>",
"    ]. Similarly, in a study of 130,000 persons in western Kenya the mortality rate for children &lt;1 year was significantly decreased after 4 years of ITN use with no increase in mortality among older children [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/34\">",
"     34",
"    </a>",
"    ]. Serological studies have shown diminished levels of antimalaria antibodies after prolonged ITN use in a community, but the clinical significance of this observation is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There has been concern about the emergence of pyrethroid resistance among major mosquito vectors; laboratory detection of resistance genes may or may not correlate with epidemiologic observations. While genes for pyrethroid resistance have been demonstrated among mosquito vectors in the Ivory Coast, ITNs remain effective for killing mosquitoes and preventing malaria [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/36\">",
"     36",
"    </a>",
"    ]. However, failure of pyrethroid-based ITNs to kill mosquitoes has been reported in west Africa [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of pyrethroids for ITNs is more economical than indoor residual spraying (IRS). In a trial comparing pyrethroid for ITN versus IRS, comparable effects on mosquito populations and malaria morbidity were observed, although IRS required six times as much insecticide as bed net treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Indoor residual spraying",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indoor residual spraying (IRS) involves spraying insecticide on indoor residential walls and ceilings; depending on the insecticide and surface, the effect can last for extended periods. IRS is performed with hand-operated compression sprayers containing an aqueous suspension of insecticide. Spray teams must be trained and supervised closely in applying the correct dose to walls and ceilings and protecting themselves from toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/40\">",
"     40",
"    </a>",
"    ]. Frequency of IRS application varies from once or twice yearly for organochlorine compounds (eg, DDT) to three or more times for organophosphates (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/21/12627?source=see_link\">",
"     malathion",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mosquito contact with insecticide-treated surfaces is generally lethal; sublethal exposure drives mosquitoes outside the house. Ideally the mosquito is killed or repelled before feeding on humans within the dwelling [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/42\">",
"     42",
"    </a>",
"    ]. Widespread community IRS reduces the proportion of mosquitoes surviving long enough to transmit malaria, since each mosquito attempt at a blood meal results in a potentially lethal insecticide exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/28,41,43\">",
"     28,41,43",
"    </a>",
"    ]. Community health education about IRS is essential; spraying may require furniture rearrangements, the walls may become streaked with chemical treatments, and there may be a residual odor from the IRS.",
"   </p>",
"   <p>",
"    DDT (Dichloro-Diphenyl-Trichloroethane) is a widely used IRS insecticide based on its efficacy, low cost, low toxicity, and length of effect. Use of DDT is approved for indoor vector control by a global treaty to protect human health and the environment from chemicals (persistent organic pollutants or POPS) that remain in the environment for long periods. The exemption for human health purposes requires that rigorous measures are taken to avoid outdoor agricultural use where DDT may cause harm to wildlife [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/44\">",
"     44",
"    </a>",
"    ]. DDT was used for IRS programs that achieved malaria elimination in many areas in the 1940s and 1950s (including the southern United States, most Caribbean islands, southern Europe, most of the former USSR, and Taiwan). It has also been used successfully for reducing malaria prevalence in south Asia, southern Africa, South America, and Zanzibar [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/8,45,46\">",
"     8,45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the mid-1990s, many regions switched from DDT to pyrethroids for IRS. This resulted from environmental concerns about toxicity and pressure against DDT use, and there has been a reduction in production of the compound. Subsequently, resistance to pyrethroids emerged rapidly among An. funestus mosquitoes; in Kwazulu-Natal, South Africa, the incidence of malaria increased greatly. A return to DDT (together with a switch in the first line antimalarial drug to artemisinin-based compounds) reduced the malaria incidence rate by 91 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In regions where Anopheles populations have developed resistance to DDT, organophosphates, carbamates, or pyrethroids have been used. In the early 2000s, WHO again endorsed using DDT for IRS where the public health consequences (the malaria burden) outweighed the possible environmental and wildlife toxic effects. In mid-2009, WHO modified their position again stating that DDT should be phased out over time to be replaced with other insecticides.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Larval control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to availability of insecticides for use against adult mosquitoes, a concerted effort was directed toward making potential breeding sites unsuitable for Anopheles larvae. Famous examples include fluctuation of water levels in the reservoirs of the Tennessee Valley Authority and the draining of the Pontine Marshes near Rome [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although ITNs and IRS have become the most important measures for mosquito vector control by targeting the adult Anopheles mosquito, there are conditions in which larval control can still play a useful role, including urban areas, refugee camps and other epidemic-prone areas. Larval control is challenging in that virtually all potential breeding places within mosquito flight range of the human community must be identified and addressed. To prevent anopheline population explosions, drainage and filling of water collection sites as well as careful management of large engineering projects such as dam and building construction are needed.",
"   </p>",
"   <p>",
"    Larvivorous fish species (eg, Gambusia and Poecilia) are avid feeders on mosquito larvae and may be used to stock village wells and ponds (the breeding places of local mosquito vectors). This strategy was implemented in a series of villages in south India; from 1998 (over one year after release of fish) until 2003, no malaria cases were detected in the villages [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. This method also allows villagers to continue their traditions of raising indoor silkworm moths the without threat of insecticide damage.",
"   </p>",
"   <p>",
"    Insect growth regulators such as pyriproxyfen (in a sand granule formulation) may be used in water filled pits to prevent metamorphosis from larva to pupa to adult. This technique was used in Sri Lanka, where malaria eradication was nearly achieved in the 1960s but disease persisted in areas where pits were dug in search of gems (subsequently the pits filled with rainwater and became breeding sites for malaria vectors) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/49\">",
"     49",
"    </a>",
"    ]. Treatment of all the pits in four villages achieved 24 percent reduction in incidence of malaria cases (compared with untreated villages). Retreatment two to three times a year was sufficient.",
"   </p>",
"   <p>",
"    Use of larval control techniques in Africa has been nearly impossible since breeding sites of An. gambiae tend to be small and impermanent. However, a major reduction in the density of adult An. gambiae was achieved in a Kenyan village by use of the bacterial toxin Bacillus thuringiensis israelensis (Bti). This toxin is highly specific for mosquito larvae and targets very few other species [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/50\">",
"     50",
"    </a>",
"    ]. Bti has a short half life, and over 400 potential breeding sites were checked weekly and retreated, if necessary. An. funestus may be a more feasible target for antilarval control measures in Africa given that its breeding sites are larger and more permanent.",
"   </p>",
"   <p>",
"    A problem with many of the biological control approaches to larval control has been that they are difficult to expand to large-scale or national public usefulness. This is because of the site-specific nature of the research and other constraints. In some projects the imported fish species did not adapt to local conditions and they were avidly consumed by the human populations they were to protect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Genetic control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic strategies for malaria control entail using male mosquitoes to introduce genetic factors that prevent the eggs from hatching, prevent the larvae from surviving, or produce adult insects incapable of transmitting human disease. Despite years of investigation genetic control remains but a promising research theme.",
"   </p>",
"   <p>",
"    To prevent eggs from hatching or larvae from surviving, males carrying sterilizing factors (dominant lethal mutations introduced by irradiation of the adult male) compete for mates in a target population of females who have not already mated with fertile males [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/51\">",
"     51",
"    </a>",
"    ]. This is known as the sterile insect technique (SIT). Experience with SIT for Anopheles mosquitoes is limited, although the technique has been successful for eradication of other pests [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To produce adult insects incapable of transmitting disease, a transgenic system has been developed which greatly reduces susceptibility of An. stephensi to infection with rodent malaria [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/53\">",
"     53",
"    </a>",
"    ]. It is hoped that similar approaches will soon produce strains completely non-susceptible to P. falciparum [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. However, the optimal approach for creating genetic factors that selectively incorporate themselves into later generations in a wild population is under intense study, but remains uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/55-57\">",
"     55-57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Choice of method",
"    </span>",
"    &nbsp;&mdash;&nbsp;The behavior of the vector is important for determining the choice of control method [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/28\">",
"     28",
"    </a>",
"    ]. For mosquitoes that prefer to rest indoors (endophilic), and feed indoors (endophagic) at night, both IRS and ITN are effective methods of control. For mosquitoes that prefer to rest outdoors (exophilic) and feed outdoors (exophagic) earlier in the day (eg, the South American vector An. albimanus), the use of repellents may be the only feasible method of control. If the vector has clearly defined breeding sites (for example, An. stephensi), then larval control measures can be applied [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/28\">",
"     28",
"    </a>",
"    ]. However, an integrated control strategy is often the most successful approach [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies carried out prior to the implementation of a mosquito control program should survey the local mosquito population, identify vector species, and identify the most anthropophilic species [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/58\">",
"     58",
"    </a>",
"    ]. The type and degree of insecticide resistance present in the mosquito population should also be investigated [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/59,60\">",
"     59,60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Personal protection",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Mosquito repellents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repellents applied to exposed skin may be used to protect against mosquito bites. Effective repellents include synthetic preparations such as DEET (N,N-diethyl-m-toluamide), Picardin (KBR3023) and IR 3535, as well as PMD (P-MENTHANE-3,8-DIOL), which is derived from lemon eucalyptus [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/61\">",
"     61",
"    </a>",
"    ]. For maximal protection against mosquitoes, DEET is preferable over other agents. Selection and use of mosquito repellents are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/1/43031?source=see_link\">",
"     \"Prevention of arthropod and insect bites: Repellents and other measures\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of mosquito repellents for protection against malaria is variable depending on the transmitting mosquito vector. Repellents are most effective in areas where vectors feed in the early evening (as with many South American and Asian vectors), rather than later in the night (as with African vectors such as An. gambiae). Repellents may also be more effective in regions with zoophilic vectors as in the Americas and south Asia (where mosquitoes may be diverted from a repellent-treated person to an animal), than in regions with anthropophilic vectors (Africa). This was illustrated in a cluster-randomized study of 4008 participants in rural Bolivia, where the principal vector is An. darlingi [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/62\">",
"     62",
"    </a>",
"    ]. All participants slept under treated nets; one group also used a plant-based insect repellent each evening while a second group used placebo. Rates of P. vivax malaria episodes were reduced by 80 percent. A protective but not significant effect was observed for P. falciparum as the number of cases was small.",
"   </p>",
"   <p>",
"    Repellents have also been protective against malaria in refugee camps on the Pakistan-Afghan border; in this region the main vectors of malaria are An. stephensi, An. culicifacies, An. pulcherrimus and An. nigerrimus [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/63\">",
"     63",
"    </a>",
"    ]. Among 127 families randomized to receive repellent soap (20 percent",
"    <span class=\"nowrap\">",
"     DEET/0.5",
"    </span>",
"    percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/22/28004?source=see_link\">",
"     permethrin",
"    </a>",
"    ) or placebo, fewer cases of P. falciparum malaria were observed among those using repellent soap (3.7 versus 8.9 percent). There was no effect against P. vivax malaria.",
"   </p>",
"   <p>",
"    In regions where vectors feed in the middle of the night, repellents might not increase the degree of protection afforded by use of insecticide treated nets alone; this requires further evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Vaccine development",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many different antigens have been identified as potential targets for malaria vaccine development. Thus far the most promising appears to be the repetitive sequence of four amino acids in the circumsporozoite antigen on the surface of the P. falciparum sporozoite (",
"    <a class=\"graphic graphic_figure graphicRef70176 \" href=\"UTD.htm?16/23/16760\">",
"     figure 3",
"    </a>",
"    ). This antigen is the basis for the",
"    <span class=\"nowrap\">",
"     RTS,S/AS01",
"    </span>",
"    vaccine, which consists of a recombinant fusion protein. 'RTS' stands for 'repeat T epitopes' derived from the circumsporozoite protein; 'S' stands for the S antigen derived from hepatitis B surface antigen [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/64\">",
"     64",
"    </a>",
"    ]. AS01 is a proprietary adjuvant.",
"   </p>",
"   <p>",
"    Phase 2 trials of this vaccine demonstrated a 30 to 60 percent reduction in the incidence of malaria infection with a favorable safety profile [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/65\">",
"     65",
"    </a>",
"    ]. A large scale phase 3 study is underway in Africa; preliminary results one year following vaccination among children 5 to 17 months of age demonstrate similar reduction in malaria incidence and severe malaria episodes as the phase 2 studies [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/66\">",
"     66",
"    </a>",
"    ]. Preliminary results among infants 6 to 12 weeks of age demonstrate lower reduction in malaria incidence (31 percent) and severe malaria (26 percent) than among children 5 to 17 months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of the vaccine appears to wane over time. Among 223 vaccinated children, the efficacy of the",
"    <span class=\"nowrap\">",
"     RTS,S/ASO1E",
"    </span>",
"    vaccine over a four-year period was 16 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/68\">",
"     68",
"    </a>",
"    ]. Pooled data from seven phase IIb trials in which RTS,S was administered to 4453 participants in six African countries noted substantial heterogeneity in efficacy among population subgroups; the vaccine efficacy was lowest in areas with high transmission intensity and declined to zero three years after vaccination [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/69\">",
"     69",
"    </a>",
"    ]. We await the final reports evaluating outcomes and follow-up after booster vaccination.",
"   </p>",
"   <p>",
"    A successful malaria vaccine (particularly one targeting gametocytes) used in conjunction with other control interventions will reduce greatly the global disease burden due to malaria [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/70,71\">",
"     70,71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical, epidemiological, entomological, and parasitological surveillance of malaria is required to follow the progress of malaria control and eradication programs. Emphasis should be on clinical manifestations of illness in hospitals and health units initially (passive surveillance) and then on rural communities. As elimination is undertaken, active detection of malaria infections house by house (active surveillance) will become essential. Modern information technologies (eg, cell phones, hand-held data entry devices, computerized reporting, feedback bulletins) will be necessary to assure prompt and accurate sharing of information. Surveillance of morbidity, mortality, disability, drug and insecticide resistance, and of commodities will be the key to malaria elimination and ultimately eradication [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A review of antimalarial drug quality in Asia and Africa showed an alarming prevalence of counterfeit drugs on the shelves of pharmacies in multiple countries [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16473/abstract/73\">",
"     73",
"    </a>",
"    ]; up to 36 percent of antimalarial drugs and 43 percent of the artemisinin combination drugs were falsified. This criminal behavior requires more attention, including definition of the problem locally, scientific and technological means to identify rapidly poor quality drugs and other commodities (eg, diagnostic tests), and regulatory action.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Malaria is the most important parasitic disease of humans, with transmission in over 100 countries affecting close to three billion people and causing one to two million deaths each year. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To consider interventions for malaria control it is important to define goals of control, elimination and eradication. Control is reduction of disease incidence and prevalence to levels that do not pose a threat to public health or that are acceptable to a community. Elimination is reduction to zero transmission in humans in a defined geographic area. Eradication is global elimination of human disease. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intermittent preventive treatment (IPT) appears to be useful for reducing the risk of malaria infection among individuals at high risk, particularly pregnant women. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Antimalarial drugs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mosquito vector control methods include use of insecticide treated nets (ITNs), household insecticide residual spraying (IRS), larval control, and, genetic control methods. Since effective insecticides for use against adult Anopheles have become available, ITNs and IRS have become the most important measures for mosquito vector control. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Mosquito vector control'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The efficacy of mosquito repellents for protection against malaria is variable depending on the transmitting mosquito vector. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Mosquito repellents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Phase 2 and phase 3 trials of the",
"      <span class=\"nowrap\">",
"       RTS,S/AS01",
"      </span>",
"      vaccine appeared promising thus far. A successful malaria vaccine used in conjunction with other control interventions could reduce the global disease burden of malaria. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Vaccine development'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Measuring progress by continuous, timely, widely-shared surveillance information is the key to control and eradication. Surveillance of the quality of anti-malarial drugs (and other commodities) is essential to assure effective treatment and prevention. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Surveillance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     WHO, World Malaria Report, 2008. Geneva, Switzerland.",
"    </li>",
"    <li>",
"     WHO. World Malaria Report. 2011. file://www.who.int/malaria/world_malaria_report_2011/en/ (Accessed on February 28, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16473/abstract/3\">",
"      Murray CJ, Rosenfeld LC, Lim SS, et al. Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet 2012; 379:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16473/abstract/4\">",
"      Filler S, Causer LM, Newman RD, et al. Malaria surveillance--United States, 2001. MMWR Surveill Summ 2003; 52:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16473/abstract/5\">",
"      Guerra CA, Gikandi PW, Tatem AJ, et al. The limits and intensity of Plasmodium falciparum transmission: implications for malaria control and elimination worldwide. PLoS Med 2008; 5:e38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16473/abstract/6\">",
"      Snow RW, Guerra CA, Noor AM, et al. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 2005; 434:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16473/abstract/7\">",
"      Price RN, Tjitra E, Guerra CA, et al. Vivax malaria: neglected and not benign. Am J Trop Med Hyg 2007; 77:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16473/abstract/8\">",
"      Breman JG. Eradicating malaria. Sci Prog 2009; 92:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16473/abstract/9\">",
"      White NJ. Plasmodium knowlesi: the fifth human malaria parasite. Clin Infect Dis 2008; 46:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16473/abstract/10\">",
"      Smith T, Maire N, Dietz K, et al. Relationship between the entomologic inoculation rate and the force of infection for Plasmodium falciparum malaria. Am J Trop Med Hyg 2006; 75:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16473/abstract/11\">",
"      Kiszewski AE, Teklehaimanot A. A review of the clinical and epidemiologic burdens of epidemic malaria. Am J Trop Med Hyg 2004; 71:128.",
"     </a>",
"    </li>",
"    <li>",
"     WHO Global Malaria Control and Elimination: report of a technical review 17-18 January 2008. Geneva, pp. 1-47.",
"    </li>",
"    <li>",
"     Bruce Chwatt LJ. Essential Malariology, Wiley Medical, 1985. p.193.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16473/abstract/14\">",
"      Laufer MK, Takala-Harrison S, Dzinjalamala FK, et al. Return of chloroquine-susceptible falciparum malaria in Malawi was a reexpansion of diverse susceptible parasites. J Infect Dis 2010; 202:801.",
"     </a>",
"    </li>",
"    <li>",
"     World Bank, Millennium Development Goals, 2005.",
"    </li>",
"    <li>",
"     Teklehaimanot A, Singer B, Spielman A, et al. UN Millennium Project. Coming to grips with malaria in the new millennium. Task Force on HIV/AIDS, malaria, TB, and access to essential medicines. Working Group on Malaria, 2005, p. 10.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16473/abstract/17\">",
"      Skarbinski J, Ouma PO, Causer LM, et al. Effect of malaria rapid diagnostic tests on the management of uncomplicated malaria with artemether-lumefantrine in Kenya: a cluster randomized trial. Am J Trop Med Hyg 2009; 80:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16473/abstract/18\">",
"      Breman JG. The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden. Am J Trop Med Hyg 2001; 64:1.",
"     </a>",
"    </li>",
"    <li>",
"     WHO, Chemotherapy of malaria, 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16473/abstract/20\">",
"      Crawley J, Sismanidis C, Goodman T, et al. Effect of intermittent preventive treatment for malaria during infancy on serological responses to measles and other vaccines used in the Expanded Programme on Immunization: results from five randomised controlled trials. Lancet 2012; 380:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16473/abstract/21\">",
"      Aponte JJ, Schellenberg D, Egan A, et al. Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials. Lancet 2009; 374:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16473/abstract/22\">",
"      Gosling RD, Gesase S, Mosha JF, et al. Protective efficacy and safety of three antimalarial regimens for intermittent preventive treatment for malaria in infants: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 374:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16473/abstract/23\">",
"      Benn CS, Aaby P. Does IPTi decrease malaria morbidity but not mortality? Lancet 2012; 380:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16473/abstract/24\">",
"      Pearce RJ, Ord R, Kaur H, et al. A community-randomized evaluation of the effect of intermittent preventive treatment in infants on antimalarial drug resistance in southern Tanzania. J Infect Dis 2013; 207:848.",
"     </a>",
"    </li>",
"    <li>",
"     WHO. Report of the Technical Consultation on Intermittent Preventive Treatment in Infants (IPTi), Technical Expert Group on Preventive Chemotherapy, Geneva: WHO 2009:1-11. file://www.who.int/malaria/publications/atoz/tegconsultiptiapr2009report.pdf (Accessed on March 13, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16473/abstract/26\">",
"      Meremikwu MM, Donegan S, Sinclair D, et al. Intermittent preventive treatment for malaria in children living in areas with seasonal transmission. Cochrane Database Syst Rev 2012; 2:CD003756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16473/abstract/27\">",
"      Hamon J. Les moustiques anthropophiles de la r&eacute;gion de Bobo Dioulasso: cycles d'aggressivit&eacute; et variations saisonni&egrave;res. Annales de la Societ&eacute; d'Entomologie de la France 1963; 132:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16473/abstract/28\">",
"      Pates H, Curtis C. Mosquito behavior and vector control. Annu Rev Entomol 2005; 50:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16473/abstract/29\">",
"      Curtis CF, Maxwell CA, Magesa SM, et al. Insecticide-treated bed-nets for malaria mosquito control. J Am Mosq Control Assoc 2006; 22:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16473/abstract/30\">",
"      Velema JP. Malaria, bednets, and mortality. Lancet 1991; 338:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16473/abstract/31\">",
"      Wang D, Kamijima M, Imai R, et al. Biological monitoring of pyrethroid exposure of pest control workers in Japan. J Occup Health 2007; 49:509.",
"     </a>",
"    </li>",
"    <li>",
"     Lengeler C. Insecticide Treated Bednets and Curtains for Malaria Control: A Cochrane Review. The Cochrane Library. Issue 3, 2005. Oxford Update Software Ltd.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16473/abstract/33\">",
"      Zaim M, Aitio A, Nakashima N. Safety of pyrethroid-treated mosquito nets. Med Vet Entomol 2000; 14:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16473/abstract/34\">",
"      Lindblade KA, Eisele TP, Gimnig JE, et al. Sustainability of reductions in malaria transmission and infant mortality in western Kenya with use of insecticide-treated bednets: 4 to 6 years of follow-up. JAMA 2004; 291:2571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16473/abstract/35\">",
"      Askjaer N, Maxwell C, Chambo W, et al. Insecticide-treated bed nets reduce plasma antibody levels and limit the repertoire of antibodies to Plasmodium falciparum variant surface antigens. Clin Diagn Lab Immunol 2001; 8:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16473/abstract/36\">",
"      Henry MC, Assi SB, Rogier C, et al. Protective efficacy of lambda-cyhalothrin treated nets in Anopheles gambiae pyrethroid resistance areas of C&ocirc;te d'Ivoire. Am J Trop Med Hyg 2005; 73:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16473/abstract/37\">",
"      Trape JF, Tall A, Diagne N, et al. Malaria morbidity and pyrethroid resistance after the introduction of insecticide-treated bednets and artemisinin-based combination therapies: a longitudinal study. Lancet Infect Dis 2011; 11:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16473/abstract/38\">",
"      Asidi A, N'Guessan R, Akogbeto M, et al. Loss of household protection from use of insecticide-treated nets against pyrethroid-resistant mosquitoes, benin. Emerg Infect Dis 2012; 18:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16473/abstract/39\">",
"      Curtis CF, Maxwell CA, Finch RJ, Njunwa KJ. A comparison of use of a pyrethroid either for house spraying or for bednet treatment against malaria vectors. Trop Med Int Health 1998; 3:619.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Manual for indoor residual spraying application of residual sprays for vector control. WHO/CDS/WHOPES/GCDPP/2000.3 Rev.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16473/abstract/41\">",
"      Sadasivaiah S, Tozan Y, Breman JG. Dichlorodiphenyltrichloroethane (DDT) for indoor residual spraying in Africa: how can it be used for malaria control? Am J Trop Med Hyg 2007; 77:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16473/abstract/42\">",
"      Roberts DR, Alecrim WD. Behavioral response of Anopheles darlingi to DDT-sprayed house walls in Amazonia. Bull Pan Am Health Organ 1991; 25:210.",
"     </a>",
"    </li>",
"    <li>",
"     MacDonald G. Epidemiology and Control of Malaria, Oxford University Press, London 1957.",
"    </li>",
"    <li>",
"     Stockholm Convention on Persistent Organic Pollutants. file://chm.pops.int/ (Accessed on September 01, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16473/abstract/45\">",
"      Giglioli G. Changes in the pattern of mortality following the eradication of hyperendemic malaria from a highly susceptible community. Bull World Health Organ 1972; 46:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16473/abstract/46\">",
"      Maharaj R, Mthembu DJ, Sharp BL. Impact of DDT re-introduction on malaria transmission in KwaZulu-Natal. S Afr Med J 2005; 95:871.",
"     </a>",
"    </li>",
"    <li>",
"     Curtis CF. Integrated vector management for malaria. In: Integrated Pest Management, Radcliffe E (Ed), Cambridge University Press, Cambridge 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16473/abstract/48\">",
"      Ghosh SK, Tiwari SN, Sathyanarayan TS, et al. Larvivorous fish in wells target the malaria vector sibling species of the Anopheles culicifacies complex in villages in Karnataka, India. Trans R Soc Trop Med Hyg 2005; 99:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16473/abstract/49\">",
"      Yapabandara AM, Curtis CF, Wickramasinghe MB, Fernando WP. Control of malaria vectors with the insect growth regulator pyriproxyfen in a gem-mining area in Sri Lanka. Acta Trop 2001; 80:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16473/abstract/50\">",
"      Fillinger U, Lindsay SW. Suppression of exposure to malaria vectors by an order of magnitude using microbial larvicides in rural Kenya. Trop Med Int Health 2006; 11:1629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16473/abstract/51\">",
"      Andreasen MH, Curtis CF. Optimal life stage for radiation sterilization of Anopheles males and their fitness for release. Med Vet Entomol 2005; 19:238.",
"     </a>",
"    </li>",
"    <li>",
"     Klassen W, Curtis CF. History of the Sterile Insect Technique (SIT). In: The Sterile Insect Technique: Principles and Practice in Area-wide Integrated Pest Management, Dyck VA, Hendrichs L, Robinson AS (Eds), Springer, Heidelberg, Germany 2005. p.3.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16473/abstract/53\">",
"      Catteruccia F, Benton JP, Crisanti A. An Anopheles transgenic sexing strain for vector control. Nat Biotechnol 2005; 23:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16473/abstract/54\">",
"      Ito J, Ghosh A, Moreira LA, et al. Transgenic anopheline mosquitoes impaired in transmission of a malaria parasite. Nature 2002; 417:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16473/abstract/55\">",
"      Chen CH, Huang H, Ward CM, et al. A synthetic maternal-effect selfish genetic element drives population replacement in Drosophila. Science 2007; 316:597.",
"     </a>",
"    </li>",
"    <li>",
"     Burt A, Trivers R. Genes in Conflict, Belknap Press, Harvard University, 2006.",
"    </li>",
"    <li>",
"     Curtis CF, Coleman PG, Kelly D. Advantages and limitations of transgenic vector control: sterile males versus gene drivers. In: Genetically Modified Mosquitoes for Malaria Control, Boete C (Ed), Landes Bioscience, Georgetown, Texas 2006. p.60.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16473/abstract/58\">",
"      Rowland M, Mohammed N, Rehman H, et al. Anopheline vectors and malaria transmission in eastern Afghanistan. Trans R Soc Trop Med Hyg 2002; 96:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16473/abstract/59\">",
"      Van Bortel W, Trung HD, Thuan le K, et al. The insecticide resistance status of malaria vectors in the Mekong region. Malar J 2008; 7:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16473/abstract/60\">",
"      Chandre F, Darrier F, Manga L, et al. Status of pyrethroid resistance in Anopheles gambiae sensu lato. Bull World Health Organ 1999; 77:230.",
"     </a>",
"    </li>",
"    <li>",
"     Debboun M, Frances SP, Strickman D. Insect Repellents, CRC Press, Boca Raton 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16473/abstract/62\">",
"      Hill N, Lenglet A, Arn&eacute;z AM, Carneiro I. Plant based insect repellent and insecticide treated bed nets to protect against malaria in areas of early evening biting vectors: double blind randomised placebo controlled clinical trial in the Bolivian Amazon. BMJ 2007; 335:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16473/abstract/63\">",
"      Rowland M, Downey G, Rab A, et al. DEET mosquito repellent provides personal protection against malaria: a household randomized trial in an Afghan refugee camp in Pakistan. Trop Med Int Health 2004; 9:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16473/abstract/64\">",
"      Bejon P, Lusingu J, Olotu A, et al. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med 2008; 359:2521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16473/abstract/65\">",
"      Agnandji ST, Asante KP, Lyimo J, et al. Evaluation of the safety and immunogenicity of the RTS,S/AS01E malaria candidate vaccine when integrated in the expanded program of immunization. J Infect Dis 2010; 202:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16473/abstract/66\">",
"      Agnandji ST, Lell B, Soulanoudjingar SS, et al. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med 2011; 365:1863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16473/abstract/67\">",
"      RTS,S Clinical Trials Partnership, Agnandji ST, Lell B, et al. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med 2012; 367:2284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16473/abstract/68\">",
"      Olotu A, Fegan G, Wambua J, et al. Four-year efficacy of RTS,S/AS01E and its interaction with malaria exposure. N Engl J Med 2013; 368:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16473/abstract/69\">",
"      Bejon P, White MT, Olotu A, et al. Efficacy of RTS,S malaria vaccines: individual-participant pooled analysis of phase 2 data. Lancet Infect Dis 2013; 13:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16473/abstract/70\">",
"      Abdulla S, Oberholzer R, Juma O, et al. Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants. N Engl J Med 2008; 359:2533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16473/abstract/71\">",
"      Breman JG, Plowe CV. A malaria vaccine for control: more progress. J Infect Dis 2009; 200:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16473/abstract/72\">",
"      Breman JG, Holloway CN. Malaria surveillance counts. Am J Trop Med Hyg 2007; 77:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16473/abstract/73\">",
"      Nayyar GM, Breman JG, Newton PN, Herrington J. Poor-quality antimalarial drugs in southeast Asia and sub-Saharan Africa. Lancet Infect Dis 2012; 12:488.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5702 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-806F72AFFC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_5_16473=[""].join("\n");
var outline_f16_5_16473=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23968136\">",
"      Chloroquine susceptibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      STRATEGIES FOR CONTROL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Antimalarial drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29018577\">",
"      - Intermittent preventive treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Mosquito vector control",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Insecticide treated nets",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Indoor residual spraying",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Larval control",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Genetic control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Choice of method",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Personal protection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Mosquito repellents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Vaccine development",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Surveillance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5702\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5702|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/32/39430\" title=\"figure 1\">",
"      Global distribution malaria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/7/25726\" title=\"figure 2\">",
"      Malaria eradication phases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/23/16760\" title=\"figure 3\">",
"      Plasmodium life cycle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5702|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/50/32556\" title=\"table 1\">",
"      Malaria world epidemiology",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10248?source=related_link\">",
"      Diagnosis of malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/1/43031?source=related_link\">",
"      Prevention of arthropod and insect bites: Repellents and other measures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20695?source=related_link\">",
"      Treatment and prevention of malaria in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/41/25241?source=related_link\">",
"      Treatment of uncomplicated falciparum malaria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_5_16474="Liver transplantation for hepatitis C virus infection";
var content_f16_5_16474=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Liver transplantation for hepatitis C virus infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/5/16474/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/5/16474/contributors\">",
"     Elizabeth C Verna, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/5/16474/contributors\">",
"     Robert S Brown, Jr, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/5/16474/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/5/16474/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/5/16474/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/5/16474/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/5/16474/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis C virus (HCV) infection causes about 40 percent of all chronic liver disease in the United States and HCV-associated cirrhosis is the most common indication for orthotopic liver transplantation (OLT) among adults [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. HCV infection remains a problem after transplantation and recurrent hepatic infection is the leading cause of graft failure.",
"   </p>",
"   <p>",
"    The major issues related to HCV following liver transplantation will be reviewed here. Similar problems arise in patients with HCV who undergo other forms of organ transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31289?source=see_link\">",
"     \"Hepatitis C virus infection and renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The natural history and treatment of HCV, as well as the selection of patients for liver transplantation is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31530?source=see_link\">",
"     \"Clinical manifestations and natural history of chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/45/43735?source=see_link\">",
"     \"Overview of the management of chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24314?source=see_link\">",
"     \"Treatment regimens for chronic hepatitis C virus genotype 1\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/37/600?source=see_link\">",
"     \"Treatment regimens for chronic hepatitis C virus genotypes 2, 3, and 4\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/61/25559?source=see_link\">",
"     \"Patient selection for liver transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrence of HCV following orthotopic liver transplantation (OLT) occurs in over 95 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Nucleotide sequence studies of HCV demonstrate that the disease following OLT results from the same viral strain present before OLT. Virologic reinfection at the time of transplantation is not surprising, since almost all patients are viremic at this time [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/3\">",
"     3",
"    </a>",
"    ]. Reinfection occurs during reperfusion of the allograft in the operating room, and viral titers reach pretransplant levels within 72 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/5\">",
"     5",
"    </a>",
"    ]. Furthermore, peripheral monocytes may also harbor virus and act as a source for reinfection of the donor liver [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/6\">",
"     6",
"    </a>",
"    ]. De novo infection in previously HCV-negative patients can result from transfusion of blood products during OLT but has become rare since 1992 due to blood product screening.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Variables that influence the progression of recurrent HCV following orthotopic liver transplantation (OLT) are incompletely understood, but donor characteristics (donor type, age), viral characteristics (genotype, viral load), the inflammatory grade of the explanted liver, and the patient's immune status and immunosuppressive regimen may be important [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/7-20\">",
"     7-20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Donor characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Of the other donor characteristics that have been investigated, the strongest predictor of outcomes is donor age. Although grafts from donors aged 60 to 80 years function without a survival disadvantage in non-HCV infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/21\">",
"     21",
"    </a>",
"    ], HCV recurrence may be more severe when older donors are used [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/20,22-25\">",
"     20,22-25",
"    </a>",
"    ]. This diminished graft survival may even be seen in donors in their fourth and fifth decades, and the mechanism of interaction is unknown.",
"   </p>",
"   <p>",
"    The type of donor used may have an impact on patient and graft survival. Adult-to-adult living donor liver transplantation has been performed in the United States since 1998 and there were early reports of more severe HCV recurrence in this population [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. However, several larger studies have not confirmed this finding [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/28-33\">",
"     28-33",
"    </a>",
"    ]. A meta-analysis of 14 studies with 2024 patients with HCV who received a transplantation from a living donor found comparable patient survival rates at years one through five [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/34\">",
"     34",
"    </a>",
"    ]. Graft survival rates at years one and three were lower among those who received a graft from a living donor, but were similar at years two, four, and five.",
"   </p>",
"   <p>",
"    A multicenter living donor liver transplantation cohort revealed that the experience of the transplantation center may be the driving factor in predicting patient outcomes in living donor recipients with HCV [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/35\">",
"     35",
"    </a>",
"    ]. Patient and graft survival were similar among recipients of living or deceased organs when performed in centers that had performed at least 20 living donor transplants.",
"   </p>",
"   <p>",
"    The influence of having an HLA mismatched donor on the severity of disease recurrence following OLT remains controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/9,16\">",
"     9,16",
"    </a>",
"    ]. No consistent site of mismatch associated with disease recurrence has been identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Genotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;The influence of HCV genotype (particularly genotype 1b) on the severity of disease recurrence following OLT is also controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/9,10,13-17\">",
"     9,10,13-17",
"    </a>",
"    ]. The range of findings that have been reported can be illustrated by the following examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 652 patients from 15 European centers, genotype 1b was an independent risk factor for recurrent hepatitis but not for patient or graft survival [",
"      <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a prospective study of 60 patients from France and Japan who were followed for three years after OLT, patients infected with genotype 1b were more likely than those infected with other genotypes to develop both acute hepatitis (77 versus 40 percent) and chronic active hepatitis (59 versus 22 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a series of 42 patients from the Mayo Clinic, histologic evidence of hepatitis occurred with similar frequency (90 percent) with all genotypes [",
"      <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/13\">",
"       13",
"      </a>",
"      ]. However, development of cirrhosis was more common in those with the 1b genotype: 6 of 17 (35 percent) compared to 2 of 25 (8 percent) infected with other genotypes.",
"     </li>",
"     <li>",
"      In contrast to these findings, other larger series (124, 166, and 155 patients) found no difference in the rate or degree of hepatitis, or in graft or patient survival between 1b and non-1b patients [",
"      <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/14-16\">",
"       14-16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The degree of divergence of HCV quasispecies may also be enhanced in patients with severe recurrent HCV, suggesting that the selection for or emergence of many new HCV variants may influence disease progression [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Viral load",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum HCV RNA levels increase from 4- to 100-fold following liver transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/18\">",
"     18",
"    </a>",
"    ]. However, the relationships between pretransplant viral load, and viral load after transplantation on graft and patient survival are not well understood. Studies examining the effect of pretransplant HCV viral load on the likelihood of HCV recurrence have produced discordant results [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/10,14,15,36\">",
"     10,14,15,36",
"    </a>",
"    ]. Several reports found that pretransplant viral load did not correlate with either the likelihood or timing of HCV recurrence following OLT and did not predict the severity of liver disease when it occurred [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/10,14,36\">",
"     10,14,36",
"    </a>",
"    ]. By contrast, in one series of 166 HCV-infected liver transplantation recipients, those with HCV RNA titers greater than 1 million viral",
"    <span class=\"nowrap\">",
"     equivalents/mL",
"    </span>",
"    had a significantly lower cumulative five-year survival compared to patients with lower pretransplant titers (57 versus 84 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/15\">",
"     15",
"    </a>",
"    ]. High titers of HCV RNA in the explanted liver may also be a risk factor [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The influence of viral load following OLT is also uncertain. Some studies have suggested that viral titers in patients after transplantation do not correlate well with the severity of histologic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/38,39\">",
"     38,39",
"    </a>",
"    ], which is similar to the lack of correlation observed outside the transplantation setting. By contrast, other studies have found that an increase in viral titers was associated with worse histologic activity, increased risk of fibrosis, and decreased survival [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/18,19,40\">",
"     18,19,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H234608081\">",
"    <span class=\"h2\">",
"     Inflammatory grade",
"    </span>",
"    &nbsp;&mdash;&nbsp;The degree of inflammation present in the patient's explanted liver at the time of transplantation appears to predict fibrosis progression in recurrent HCV. This was examined in a retrospective study of 134 patients who underwent liver transplantation for HCV [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/41\">",
"     41",
"    </a>",
"    ]. Patients were divided into two groups based upon the degree of fibrosis in the explanted liver (group 1 = Ishak grade &le;4; group 2 = Ishak grade &gt;4). Five-year advanced fibrosis-free survival was significantly higher among patients in group 1 compared with group 2 (63 versus 28 percent). In addition, rates of graft loss at one and five years were significantly lower in patients in group 1 (3 versus 6 percent and 14 versus 36 percent, respectively). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/30/39398?source=see_link&amp;anchor=H2#H2\">",
"     \"Histologic scoring systems for chronic liver disease\", section on 'Knodell score'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Immunosuppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;The level and type of immunosuppression following transplantation likely influence the severity of disease recurrence. The impact of immunosuppression is most pronounced when high-intensity regimens are used to treat acute rejection, particularly with high-dose bolus steroids and anti-lymphocyte antibody preparations [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/15,42,43\">",
"     15,42,43",
"    </a>",
"    ]. There are no convincing data to support the use of any specific induction or maintenance regimen.",
"   </p>",
"   <p>",
"    Various immunosuppression strategies have been evaluated for their influence on HCV recurrence. There are convincing data that bolus doses of glucocorticoids given for rejection treatment have a negative impact on HCV recurrence, providing the rationale for clinical trials of glucocorticoid-free maintenance immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The interim, one-year report of one such study described outcomes of a glucocorticoid-free regimen involving daclizumab,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , and MMF, which was compared with tacrolimus and glucocorticoids, or tacrolimus, glucocorticoids, and MMF [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/45\">",
"     45",
"    </a>",
"    ]. Although decreased acute rejection was observed in the group receiving daclizumab, tacrolimus, and MMF, patient and graft survival as well as the rate of HCV recurrence did not differ significantly between the treatment arms. Thus, the study supports the feasibility of steroid-free maintenance immunosuppression in HCV infected patients, but its benefit on HCV recurrence was not apparent, at least in the short term.",
"   </p>",
"   <p>",
"    Another prospective multicenter study in HCV infected transplantation recipients compared steroid tapering and withdrawal within three months of transplantation with slow tapering and withdrawal over two years [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/46\">",
"     46",
"    </a>",
"    ]. Rapid tapering was significantly more likely to be associated with the development of advanced fibrosis, suggesting that abrupt changes in glucocorticoid dosing, including boluses and rapid discontinuation, may negatively impact the natural history of chronic hepatitis C post-transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     CD4 T-cell response",
"    </span>",
"    &nbsp;&mdash;&nbsp;The specific CD4 T-cell response to HCV appears to be an important determinant of viral clearance during acute HCV infection and of the severity of histologic recurrence following liver transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. The latter was illustrated in a series that included 43 patients transplanted for HCV in whom histologic recurrence of HCV was categorized as mild or absent (80 percent) or severe (20 percent). Patients with severe recurrence were far less likely to have a CD4 T-cell response to HCV antigens (0 versus 40 percent with a response to at least one HCV antigen).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL COURSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;As in the pre-transplantation setting, the clinical course following orthotopic liver transplantation (OLT) for HCV infection is variable. Five-year survival after transplantation is approximately 60 to 80 percent in most series, which is comparable to transplants performed for alcoholic liver disease, and better than historic rates for hepatitis B, hemochromatosis, or cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/9,15,17,49-52\">",
"     9,15,17,49-52",
"    </a>",
"    ]. In one series, for example, the cumulative survival for 149 patients receiving OLT for HCV following transplantation was 79, 79, and 70 percent at one, three, and five years, respectively; these results were not significantly different from 623 patients undergoing OLT for non-HCV disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/9\">",
"     9",
"    </a>",
"    ]. Another report found that the similar outcomes persisted at 10-year follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/53\">",
"     53",
"    </a>",
"    ]. Multivariate analysis on a large series of HCV patients transplanted at 15 European centers demonstrated that hepatocellular carcinoma was the only predictive factor for five-year patient or graft survival [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/32/36362?source=see_link\">",
"     \"Liver transplantation for hepatocellular carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the course of HCV infection after OLT is accelerated compared to the pretransplant setting, with 10 to 20 percent of patients developing cirrhosis only five years post-transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/7\">",
"     7",
"    </a>",
"    ]. The favorable estimates of outcomes described above may reflect publication bias, since centers with worse outcomes may be less likely to report their findings. Survival statistics from the United Network of Organ Sharing (UNOS) may provide a more comprehensive profile of transplantation outcomes.",
"   </p>",
"   <p>",
"    One such analysis of transplants conducted between 1992 and 1998 suggested that HCV-positive recipients had an increased rate of death (hazard ratio 1.23; 95% CI 1.12 to 1.35) and allograft failure (hazard ratio [HR] 1.30; 95% CI, 1.21 to 1.39) compared with transplantation of HCV negative recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/52\">",
"     52",
"    </a>",
"    ]. One-, three-, and five-year patient survival rates were 86, 78, and 70 percent, respectively (compared to 88, 82, and 77 percent, respectively, for patients without HCV). The reduction in survival persisted even after adjusting for potential confounders. The effect on survival appeared to be most pronounced in HCV-infected women. These trends persisted at least through 2001 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A second study also found that women are at increased risk for advanced recurrent HCV and graft loss [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/55\">",
"     55",
"    </a>",
"    ]. In that study, 1264 patients who underwent liver transplantation for HCV between 2002 and 2007 were followed for a median of three years. Female sex was an independent predictor of advanced recurrent disease (HR 1.3), graft loss (HR 1.3), and death (HR 1.3). The unadjusted three-year cumulated patient and graft survival rates were 75 and 74 percent, respectively, for women, and 80 and 78 percent, respectively, for men.",
"   </p>",
"   <p>",
"    Outcomes may also be influenced by the patient's race. An analysis of transplants performed in the United States between 1988 and 1996 suggested that overall survival may be slightly lower among African-Americans compared with white Americans and Hispanics (two-year survival 72 versus 80 and 77 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/53\">",
"     53",
"    </a>",
"    ]. Thus it is likely that short-term outcomes for HCV-infected patients are similar, but diverge progressively over time due to the impact of recurrent HCV and graft cirrhosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Patterns of disease recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although HCV RNA is universally detectable following transplantation, the clinical course of HCV recurrence is variable. HCV recurrence may be accompanied by the following clinical features [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/9,11,17,36,49,56\">",
"     9,11,17,36,49,56",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mild to moderate elevation of serum aminotransferases, and mild to moderate inflammation on liver biopsy (50 percent).",
"     </li>",
"     <li>",
"      Normal or near-normal serum aminotransferases, and minimal inflammatory activity on liver biopsy (20 percent).",
"     </li>",
"     <li>",
"      Moderate elevation in serum aminotransferases with progressive histologic damage observed during the first five to 10 years (20 to 40 percent).",
"     </li>",
"     <li>",
"      Rapidly progressive, cholestatic hepatitis with rapid fibrosis leading to the development of cirrhosis and graft failure (5 to 10 percent), sometimes occurring within one year following OLT [",
"      <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/4,57\">",
"       4,57",
"      </a>",
"      ]. The development of cholestatic hepatitis appears to be more common in patients with HCV viremia two weeks after transplantation and in patients with an IL28B genotype other than CC [",
"      <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/58\">",
"       58",
"      </a>",
"      ]. While survival has improved among HCV recipients in recent years, rates of recurrent severe fibrosis have remained unchanged [",
"      <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As described above, the variables leading to these patterns in individual patients are not well understood. Although several risk factors have been identified, none has been extensively validated or permitted clinically important intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/27,29,37,51,59-62\">",
"     27,29,37,51,59-62",
"    </a>",
"    ]. Early markers of likely progression to severe recurrence may include early hepatic stellate cell activation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/63\">",
"     63",
"    </a>",
"    ] and a hepatic venous pressure gradient of 6 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Transplantation of HCV infected grafts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the shortage of organs, transplantation of livers from HCV-infected donors to HCV-infected recipients has been attempted. A study evaluating the outcome of 23 such patients found that five-year survival was similar to a control group of HCV-infected recipients who had received grafts from HCV-negative donors (89 versus 88 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/64\">",
"     64",
"    </a>",
"    ]. Furthermore, an interesting observation was that patients in whom the donor strain became predominant after transplantation had significantly longer disease-free survival compared with patients who retained their original HCV strain (90 versus 15 percent). This observation was hypothesized to be related to impaired ability of CD8 and CD4 cells to recognize viral antigens presented in the context of liver transplantation with poorly matched class I and class II HLA antigens. In addition, no differences in survival have been seen in large United Network for Organ Sharing (UNOS) database studies [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/65\">",
"     65",
"    </a>",
"    ].However, a more recent multicenter retrospective study with detailed biopsy data showed that although overall survival was similar between patients who received HCV positive and negative grafts, the risk of advanced fibrosis was significantly higher in the HCV infected grafts, especially with donor age over 65 years [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Combined liver-kidney transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A subset of patients with chronic HCV has concurrent end-stage kidney disease, potentially requiring simultaneous liver and kidney transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/67-69\">",
"     67-69",
"    </a>",
"    ]. In one report, patients who underwent combined liver-kidney transplantation had similar one-year patient and graft survival rates as those who underwent liver transplantation alone (93 versus 96 percent and 93 versus 90 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study using the UNOS database, 66,026 patients underwent a liver transplantation alone, and 2327 underwent simultaneous liver-kidney transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/69\">",
"     69",
"    </a>",
"    ]. Approximately one third of the patients had HCV, and another third had unknown HCV status. One-year survival rates were slightly lower for those who received a simultaneous liver-kidney transplantation compared with a liver transplantation alone (82 versus 84 percent), though after controlling for potential confounders, patients who received a simultaneous liver-kidney transplantation had a lower risk of death than those who received a liver transplantation alone (hazard ratio [HR] 0.92, 95% confidence interval [CI] 0.86-0.99). Both groups had one-year graft survival rates of 80 percent, but on multivariable analysis, patients who received simultaneous liver-kidney transplantations were at decreased risk for graft loss (HR 0.85, 95% CI 0.79-0.92).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histologic recurrence of HCV infection following orthotopic liver transplantation (OLT) may be difficult to diagnose clinically and may be confused with acute cellular rejection in the graft. Serum ALT levels are often normal or minimally elevated with HCV infection. In addition, ELISA-based HCV assays are insensitive in immunosuppressed patients and may revert from positive to negative after OLT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41849?source=see_link\">",
"     \"Screening for and diagnosis of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are two steps involved in establishing the diagnosis of new or recurrent HCV infection following OLT [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The use of polymerase chain reaction (PCR) or transcription mediated amplification (TMA) to directly detect HCV-RNA",
"     </li>",
"     <li>",
"      Liver biopsy to confirm the diagnosis, stage the disease, and plan for treatment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Biopsy findings are typically mild and nonspecific, particularly with early recurrence. They include periportal inflammation, lobular ballooning of hepatocytes, acidophilic bodies, or lobular apoptosis. Some of these features are also seen in acute cellular rejection. Features that are supportive of recurrent HCV are lobular activity, interface hepatitis, piecemeal necrosis, and lymphocyte predominance or lymphoid follicles. Features more suggestive of rejection include a mixed cellular infiltrate (eosinophils, polymorphonuclear cells, and lymphocytes) confined to the portal triad, bile duct damage, and endotheliitis (",
"    <a class=\"graphic graphic_table graphicRef71743 \" href=\"UTD.htm?31/0/31755\">",
"     table 1",
"    </a>",
"    ). However, differentiating rejection with hepatitis C from hepatitis C alone can be difficult on pathologic grounds and is often a clinical diagnosis based on timing post-transplantation and clinical features (eg, the degree of baseline immunosuppression, prior rejection treatment) (",
"    <a class=\"graphic graphic_table graphicRef71743 \" href=\"UTD.htm?31/0/31755\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Studies have also looked for noninvasive markers of HCV recurrence. One study of 133 patients looked at an algorithm which included three serum fibrosis markers (hyaluronic acid, amino-terminal propeptide of type III procollagen, and tissue inhibitor of matrix metalloproteinase type-1 concentration) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/70\">",
"     70",
"    </a>",
"    ]. The area under the receiver operator characteristic (ROC) curve for the algorithm predicting fibrosis of stage 2 or greater (using the Scheurer classification) at one year post-transplantation was 0.78. The area under the ROC curve for the algorithm predicting a hepatic venous pressure gradient of 6 or greater at one year was 0.90.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PREVENTION OF RECURRENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several strategies for HCV treatment in the setting of transplantation have been attempted: treatment prior to transplantation to prevent infection of the graft, immediate or peri-operative prophylaxis, early preemptive HCV therapy, and treatment of established recurrent disease.",
"   </p>",
"   <p>",
"    Eradication of HCV infection prior to transplantation would be the ideal approach, as patients who undergo transplantation in the absence of viremia are much less likely to have recurrent infection. However, treatment of patients with decompensated cirrhosis is difficult. Treatment in this setting has been associated with exacerbations of encephalopathy, infections and other serious adverse events and results in low rates of viral clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/71-73\">",
"     71-73",
"    </a>",
"    ]. In addition, there is no consensus on the optimal regimen (interferon with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    ) or dosing that should be used pre-transplantation.",
"   </p>",
"   <p>",
"    A novel approach to HCV treatment prior to transplantation in advanced cirrhosis was described in a study of 124 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/72\">",
"     72",
"    </a>",
"    ]. That study used a low accelerating dose regimen (LADR). Patients were treated with a combination of interferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    with dose increases every two weeks until they reached a maximal tolerated dose. Genotype 1 patients had a 13 percent sustained virologic response (SVR) rate, whereas patients with non-1 genotypes had a 50 percent SVR rate. Fifteen patients (12 percent) experienced at least one clinically significant adverse event. The most common adverse events were infection (five patients), worsening ascites (five patients), and encephalopathy (six patients). Fifteen patients who were HCV RNA-negative following treatment went on to OLT, 12 of whom (80 percent) remained virus negative six months post-OLT.",
"   </p>",
"   <p>",
"    This approach to pre-transplantation HCV therapy has now been evaluated in a larger multicenter National Institutes of Health-sponsored study of a cohort of patients listed for liver transplantation with potential living donors",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    model for end-stage liver disease exception points for hepatocellular carcinoma. All genotype 2 and 3 patients were treated with a LADR protocol, while patients with genotype 1, 4, or 6 were assigned to LADR therapy or no pre-transplantation treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/74\">",
"     74",
"    </a>",
"    ]. Of the 30 patients with genotype 1, 4, or 6 who were treated, 23 underwent liver transplantation, 22 percent of whom achieved a post-transplantation virologic response (pTVR). Of the 29 patients with genotype 2 or 3 who were treated, 21 underwent transplantation, 29 percent of whom achieved a pTVR. Serious adverse events were similar in the treated and untreated groups, and those patients with at least 16 weeks of treatment prior to transplantation achieved the highest rates of pTVR.",
"   </p>",
"   <p>",
"    There is no consensus on the role of prophylactic or preemptive therapy following transplantation prior to HCV-related liver injury from recurrent infection [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis of 11 randomized trials with 477 patients undergoing liver transplantation for chronic HCV infection found no differences in patient survival, graft rejection, retransplantation, or HCV recurrence between patients who received antiviral therapy following transplantation and those who did not [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/75\">",
"     75",
"    </a>",
"    ]. Interventions included combination therapy (peginterferon or standard interferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    ), monotherapy (peginterferon, standard interferon, or ribavirin), and anti-HCV immune globulin. The timing of antiviral therapy varied significantly among the included trials. In some trials, treatment was initiated during the transplantation, whereas in others, patients started treatment up to 26 weeks following transplantation. However, in the majority of trials, treatment was initiated within six weeks of the transplantation.",
"   </p>",
"   <p>",
"    A subsequent randomized trial with 115 patients compared early post-transplantation prophylactic therapy starting 10 to 6 weeks post-transplantation with treatment only once there was histologic recurrence (histological activity index &ge;3",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fibrosis score &ge;2 on liver biopsy) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/76\">",
"     76",
"    </a>",
"    ]. Patients in both groups were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/27/27064?source=see_link\">",
"     pegylated interferon alfa-2a",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    . Overall, rates of survival, significant histologic recurrence, and SVR rates were similar between groups. The authors concluded that given the lack of clear benefit to the prophylactic approach and the cost and poor tolerability associated with treatment, the use of routing prophylactic therapy is not supported.",
"   </p>",
"   <p>",
"    Various approaches to immunosuppression, such as minimizing glucocorticoid exposure, have also been investigated in patients with hepatitis C [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/77\">",
"     77",
"    </a>",
"    ]. Unlike hepatitis B, no effective immunoglobulin prophylaxis exists for hepatitis C. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/12/30922?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of immunosuppression in adult liver transplantation\", section on 'Glucocorticoids and HCV'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/12/30922?source=see_link&amp;anchor=H15#H15\">",
"     \"Overview of immunosuppression in adult liver transplantation\", section on 'Calcineurin inhibitors and HCV'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38378?source=see_link\">",
"     \"Investigational therapies for hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     TREATMENT OF RECURRENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few high-quality studies to guide treatment of HCV after OLT [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/75\">",
"     75",
"    </a>",
"    ]. Treatment is generally initiated only if it is associated with significant histologic liver injury. However, the therapeutic options are limited and rigorous clinical trials are difficult to conduct in this population. In addition to changing the immunosuppressive regimens, specific treatments for HCV recurrence may include interferon,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    , and combination therapy. Some data suggest that patients receiving cyclosporin A may have marginally higher SVR rates compared with those receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Interferon monotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of established recurrent infection with interferon monotherapy has little efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/79-81\">",
"     79-81",
"    </a>",
"    ]. In a small uncontrolled pilot study, 18 patients with recurrent chronic HCV following OLT were treated with 3 million units of interferon alpha subcutaneously three times weekly for at least four months [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/80\">",
"     80",
"    </a>",
"    ]. Almost 30 percent normalized serum ALT and the HCV RNA levels decreased. However, HCV RNA remained detectable in all patients and there was no significant improvement in histology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Ribavirin monotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited data on the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    monotherapy for recurrent HCV following OLT. In one series, 18 patients with persistent elevation in serum aminotransferases following OLT were treated with ribavirin for an average of 23 months [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/82\">",
"     82",
"    </a>",
"    ]. A decrease in serum aminotransferase concentration was observed in all patients with normalization in five (28 percent). However, serum HCV RNA levels did not change during therapy, and follow-up liver biopsies showed no improvement in necroinflammation. Furthermore, patient and graft survival were similar to untreated patients. Similar findings were noted in another smaller series [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/83\">",
"     83",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28184?source=see_link\">",
"     \"Mechanism of action and efficacy of ribavirin for the treatment of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a third report comparing the efficacy of interferon alfa with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    monotherapy in 30 patients, ribavirin was superior in achieving normalization of the serum AST (93 versus 43 percent) and reducing lobular inflammation (64 versus 21 percent); however, the total histologic activity index did not improve with either therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/81\">",
"     81",
"    </a>",
"    ]. Hemolysis occurred in all ribavirin treated patients with 50 percent developing significant anemia. Given the absence of data and lack of efficacy in the non-transplantation setting, monotherapy has been abandoned by most centers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Standard interferon plus ribavirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combination therapy with standard interferon plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    given after OLT has been associated with end of treatment response rates (ETR) as high as approximately 50 percent and SVR rates of over 20 percent in some series [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/84-93\">",
"     84-93",
"    </a>",
"    ]. When the data from high quality trials were pooled, standard interferon with ribavirin was associated with a 24 percent SVR rate, a rate that was similar to that seen with pegylated interferon with ribavirin (27 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, up to 50 percent of patients drop out due to side effects, mainly anemia. The optimal duration of therapy is unclear; one study suggested that 12 months of therapy was no better than six months, even in patients with genotype 1 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/89\">",
"     89",
"    </a>",
"    ]. A case series suggested that continuous treatment may be required for patients with severe cholestatic HCV recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Peginterferon monotherapy or combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of peginterferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    has been associated with the best treatment responses overall [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/84,96-107\">",
"     84,96-107",
"    </a>",
"    ]. At least one decision-analysis suggested that such an approach was cost-effective [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/108\">",
"     108",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, most patients required dose reductions and few tolerated the full duration of treatment. A pooled analysis from over 40 treatment trials estimated that SVR rates with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    given in combination with standard interferon or peginterferon were 24 and 27 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/94\">",
"     94",
"    </a>",
"    ]. Pooled discontinuation rates were 24 and 26 percent, respectively.",
"   </p>",
"   <p>",
"    Most studies have been observational. One of the few controlled trials included 67 patients with recurrent HCV after transplantation who were randomly assigned to peginterferon alfa-2a or observation for 48 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/106\">",
"     106",
"    </a>",
"    ]. Only three patients achieved an SVR. A similar proportion of patients in the treatment and observation groups withdrew from the study. There were more episodes of rejection in the treated group, but the difference did not achieve statistical significance.",
"   </p>",
"   <p>",
"    Increasing experience with using these drugs in the post-transplantation setting has been associated with somewhat better response rates [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/104,107,109\">",
"     104,107,109",
"    </a>",
"    ]. As an example, in series of 55 patients with histologic recurrence of HCV at least one year after transplantation, end-of-treatment and SVR rates were 67 and 44 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/104\">",
"     104",
"    </a>",
"    ]. Peginterferon was discontinued due to toxicity in 29 percent of patients.",
"   </p>",
"   <p>",
"    Genetic variations in the IL28B gene appear to influence response rates to combination therapy with peginterferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/110,111\">",
"     110,111",
"    </a>",
"    ]. In a study of 67 patients who had undergone liver transplantation for HCV infection, patients who were homozygous for the C allele at the rs8099917 polymorphic site had significantly higher SVR rates than patients with heterozygous CT or homozygous TT alleles (54 versus 11 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/110\">",
"     110",
"    </a>",
"    ]. In addition, the SVR rate was higher if the donor was homozygous for the C allele (44 versus 9 percent). The highest SVR rate was seen when both the donor and recipient were homozygous for the C allele (56 percent). It was low when only one was homozygous (10 percent), and it was lowest when neither was homozygous (0 percent).",
"   </p>",
"   <p>",
"    Pilot studies have looked at the use of protease inhibitors for the treatment of HCV recurrence following liver transplantation. In a retrospective series with nine patients with HCV recurrence, seven patients completed 12 weeks of therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    , peginterferon, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/112\">",
"     112",
"    </a>",
"    ]. The other two patients discontinued therapy after 2 and 4 weeks due to adverse events. In the intention-to-treat analysis, eight patients were HCV RNA-negative at week 12, including the patient who discontinued treatment at week 4 (at which time he was HCV RNA-negative). However, the study did not report how many of the patients achieved an SVR. One concern in treating patients with telaprevir following liver transplantation is the risk of drug interactions between telaprevir and immunosuppressant medications (",
"    <a class=\"graphic graphic_table graphicRef78070 \" href=\"UTD.htm?11/30/11744\">",
"     table 2",
"    </a>",
"    ). In this study, patients had trough levels of their immunosuppressant medications monitored during and after treatment, and all patients required reductions in the doses of their immunosuppressive medications while receiving telaprevir. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24314?source=see_link&amp;anchor=H148834094#H148834094\">",
"     \"Treatment regimens for chronic hepatitis C virus genotype 1\", section on 'Drug interactions with protease inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The future of direct acting antiviral agents (protease and polymerase inhibitors) is promising, and the promise of interferon-free regimens may become a reality in the next several years. Potential limitations in implementing combination therapy with direct acting antiviral agents is that there are substantial drug interactions, particularly between protease inhibitors and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/113\">",
"     113",
"    </a>",
"    ] , and there may be an increased risk of viral",
"    <span class=\"nowrap\">",
"     breakthrough/resistance",
"    </span>",
"    with immunosuppression. As a result, these agents should currently only be used in the setting of clinical trials. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38378?source=see_link&amp;anchor=H6#H6\">",
"     \"Investigational therapies for hepatitis C virus infection\", section on 'Direct acting antiviral therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/26/15785?source=see_link\">",
"     \"Studies of telaprevir and boceprevir in the treatment of chronic hepatitis C virus genotype 1\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Retransplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disease recurrence may ultimately lead to graft failure and the need for retransplantation. Indications and contraindications for retransplantation remain unclear and practices vary widely among institutions.",
"   </p>",
"   <p>",
"    Unfortunately, the prognosis for such patients is generally poor (similar to retransplantation for other indications) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/114-122\">",
"     114-122",
"    </a>",
"    ]. This was illustrated in a multicenter study that compared survival following retransplantation in patients with recurrent HCV with survival following retransplantation for other disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/123\">",
"     123",
"    </a>",
"    ]. The one-year (69 versus 73 percent) and three-year (49 versus 55 percent) survival rates were similar in the HCV and non-HCV groups. MELD scores were not predictive of survival. Many patients were not considered eligible for retransplantation and died from recurrent disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     AASLD GUIDELINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2009 guideline from the American Association for the Study of Liver Diseases suggests that treatment of recurrent disease be initiated after demonstration of recurrent histologic disease but should be administered through caregivers experienced in transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/5/16474/abstract/124\">",
"     124",
"    </a>",
"    ]. Peginterferon alfa with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    is the preferred regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hepatitis C virus (HCV)-associated cirrhosis is the most common indication for liver transplantation in the United States. Recurrent HCV infection following orthotopic liver transplantation (OLT) remains a major cause of morbidity and mortality in the post-transplantation setting.",
"     </li>",
"     <li>",
"      The clinical course following OLT for HCV infection is variable. As a general rule, the course of HCV infection appears to be accelerated compared with the pretransplant setting. Several patterns of recurrence have been described. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical course'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many predictors of outcome following transplantation have been described, but their accuracy in predicting the course in individual patients or to guide interventions is uncertain. The use of older donors is likely associated with adverse outcomes. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of recurrent HCV infection is based upon the detection of HCV RNA, and compatible histologic characteristics. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      No effective measure to prevent recurrence has been established. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Prevention of recurrence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Optimal treatment of recurrence is unclear. We suggest a course of combination therapy with peginterferon plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      in patients with significant histologic recurrence (eg, Grade 3 or 4 inflammation or stage 2 through 4 fibrosis) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Studies are needed regarding the efficacy and safety of directly acting antivirals (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"       boceprevir",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"       telaprevir",
"      </a>",
"      ) in this setting. Therapy should be attempted only at centers with considerable experience in managing post-transplantation patients. There is no evidence to support a survival benefit for therapy; thus, preemptive therapy is not currently supported by available data.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     file://www.unos.org/ (Accessed on March 27, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/2\">",
"      Verna EC, Brown RS Jr. Hepatitis C virus and liver transplantation. Clin Liver Dis 2006; 10:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/3\">",
"      Wright TL, Donegan E, Hsu HH, et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 1992; 103:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/4\">",
"      Dickson RC, Caldwell SH, Ishitani MB, et al. Clinical and histologic patterns of early graft failure due to recurrnet hepatitis C in four patients after liver transplantation. Transplantation 1996; 61:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/5\">",
"      Garcia-Retortillo M, Forns X, Feliu A, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002; 35:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/6\">",
"      F&eacute;ray C, Samuel D, Thiers V, et al. Reinfection of liver graft by hepatitis C virus after liver transplantation. J Clin Invest 1992; 89:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/7\">",
"      Berenguer M. Natural history of recurrent hepatitis C. Liver Transpl 2002; 8:S14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/8\">",
"      Berenguer M. What determines the natural history of recurrent hepatitis C after liver transplantation? J Hepatol 2005; 42:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/9\">",
"      Gane EJ, Portmann BC, Naoumov NV, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/10\">",
"      F&eacute;ray C, Gigou M, Samuel D, et al. Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. Gastroenterology 1995; 108:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/11\">",
"      Araya V, Rakela J, Wright T. Hepatitis C after orthotopic liver transplantation. Gastroenterology 1997; 112:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/12\">",
"      Gordon SC, Bayati N, Silverman AL. Clinical outcome of hepatitis C as a function of mode of transmission. Hepatology 1998; 28:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/13\">",
"      Gordon FD, Poterucha JJ, Germer J, et al. Relationship between hepatitis C genotype and severity of recurrent hepatitis C after liver transplantation. Transplantation 1997; 63:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/14\">",
"      Zhou S, Terrault NA, Ferrell L, et al. Severity of liver disease in liver transplantation recipients with hepatitis C virus infection: relationship to genotype and level of viremia. Hepatology 1996; 24:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/15\">",
"      Charlton M, Seaberg E, Wiesner R, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998; 28:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/16\">",
"      Vargas HE, Laskus T, Wang LF, et al. The influence of hepatitis C virus genotypes on the outcome of liver transplantation. Liver Transpl Surg 1998; 4:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/17\">",
"      F&eacute;ray C, Caccamo L, Alexander GJ, et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology 1999; 117:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/18\">",
"      Gane EJ, Naoumov NV, Qian KP, et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996; 110:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/19\">",
"      Sreekumar R, Gonzalez-Koch A, Maor-Kendler Y, et al. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology 2000; 32:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/20\">",
"      Cameron AM, Ghobrial RM, Hiatt JR, et al. Effect of nonviral factors on hepatitis C recurrence after liver transplantation. Ann Surg 2006; 244:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/21\">",
"      Faber W, Seehofer D, Puhl G, et al. Donor age does not influence 12-month outcome after orthotopic liver transplantation. Transplant Proc 2011; 43:3789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/22\">",
"      Zhao Y, Lo CM, Liu CL, Fan ST. Use of elderly donors (&gt; 60 years) for liver transplantation. Asian J Surg 2004; 27:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/23\">",
"      Lake JR, Shorr JS, Steffen BJ, et al. Differential effects of donor age in liver transplant recipients infected with hepatitis B, hepatitis C and without viral hepatitis. Am J Transplant 2005; 5:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/24\">",
"      Berenguer M, Prieto M, San Juan F, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002; 36:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/25\">",
"      Burak KW, Kremers WK, Batts KP, et al. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 2002; 8:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/26\">",
"      Gaglio PJ, Malireddy S, Levitt BS, et al. Increased risk of cholestatic hepatitis C in recipients of grafts from living versus cadaveric liver donors. Liver Transpl 2003; 9:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/27\">",
"      Garcia-Retortillo M, Forns X, Llovet JM, et al. Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. Hepatology 2004; 40:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/28\">",
"      Russo MW, Galanko J, Beavers K, et al. Patient and graft survival in hepatitis C recipients after adult living donor liver transplantation in the United States. Liver Transpl 2004; 10:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/29\">",
"      Shiffman ML, Stravitz RT, Contos MJ, et al. Histologic recurrence of chronic hepatitis C virus in patients after living donor and deceased donor liver transplantation. Liver Transpl 2004; 10:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/30\">",
"      Schiano TD, Gutierrez JA, Walewski JL, et al. Accelerated hepatitis C virus kinetics but similar survival rates in recipients of liver grafts from living versus deceased donors. Hepatology 2005; 42:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/31\">",
"      Guo L, Orrego M, Rodriguez-Luna H, et al. Living donor liver transplantation for hepatitis C-related cirrhosis: no difference in histological recurrence when compared to deceased donor liver transplantation recipients. Liver Transpl 2006; 12:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/32\">",
"      Takada Y, Haga H, Ito T, et al. Clinical outcomes of living donor liver transplantation for hepatitis C virus (HCV)-positive patients. Transplantation 2006; 81:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/33\">",
"      Schmeding M, Neumann UP, Puhl G, et al. Hepatitis C recurrence and fibrosis progression are not increased after living donor liver transplantation: a single-center study of 289 patients. Liver Transpl 2007; 13:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/34\">",
"      Hu A, Liang W, Zheng Z, et al. Living donor vs. deceased donor liver transplantation for patients with hepatitis C virus-related diseases. J Hepatol 2012; 57:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/35\">",
"      Terrault NA, Lok AS, Saab S, et al. The A2ALL Study Group, Transplant center experience explains differences in the risk of graft failure between hepatitis C virus (HCV)-infected recipients of living donor (LDLT) and deceased donor (DDLT) liver transplant recipients. Hepatology 2005; 42:198A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/36\">",
"      Pessoa MG, Bzowej N, Berenguer M, et al. Evolution of hepatitis C virus quasispecies in patients with severe cholestatic hepatitis after liver transplantation. Hepatology 1999; 30:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/37\">",
"      F&eacute;ray C, Gigou M, Samuel D, et al. The course of hepatitis C virus infection after liver transplantation. Hepatology 1994; 20:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/38\">",
"      Deshpande V, Burd E, Aardema KL, et al. High levels of hepatitis C virus RNA in native livers correlate with the development of cholestatic hepatitis in liver allografts and a poor outcome. Liver Transpl 2001; 7:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/39\">",
"      Chazouilleres O, Kim M, Combs C, et al. Quantitation of hepatitis C virus RNA in liver transplant recipients. Gastroenterology 1994; 106:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/40\">",
"      Shackel NA, Jamias J, Rahman W, et al. Early high peak hepatitis C viral load levels independently predict hepatitis C-related liver failure post-liver transplantation. Liver Transpl 2009; 15:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/41\">",
"      Ghabril M, Dickson RC, Krishna M, et al. Explanted liver inflammatory grade predicts fibrosis progression in hepatitis C recurrence. Liver Transpl 2011; 17:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/42\">",
"      Freeman RB, Tran S, Lee YM, et al. Serum hepatitis C RNA titers after liver transplantation are not correlated with immunosuppression or hepatitis. Transplantation 1996; 61:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/43\">",
"      Nelson DR, Soldevila-Pico C, Reed A, et al. Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation. Liver Transpl 2001; 7:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/44\">",
"      Charlton M. Hepatitis C infection in liver transplantation. Am J Transplant 2001; 1:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/45\">",
"      Klintmalm GB, Washburn WK, Rudich SM, et al. Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study. Liver Transpl 2007; 13:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/46\">",
"      Vivarelli M, Burra P, La Barba G, et al. Influence of steroids on HCV recurrence after liver transplantation: A prospective study. J Hepatol 2007; 47:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/47\">",
"      Charlton M, Seaberg E. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Liver Transpl Surg 1999; 5:S107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/48\">",
"      Gerlach JT, Diepolder HM, Jung MC, et al. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology 1999; 117:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/49\">",
"      Rosen HR, Hinrichs DJ, Gretch DR, et al. Association of multispecific CD4(+) response to hepatitis C and severity of recurrence after liver transplantation. Gastroenterology 1999; 117:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/50\">",
"      B&ouml;ker KH, Dalley G, Bahr MJ, et al. Long-term outcome of hepatitis C virus infection after liver transplantation. Hepatology 1997; 25:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/51\">",
"      Casavilla FA, Rakela J, Kapur S, et al. Clinical outcome of patients infected with hepatitis C virus infection on survival after primary liver transplantation under tacrolimus. Liver Transpl Surg 1998; 4:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/52\">",
"      Charlton M, Ruppert K, Belle SH, et al. Long-term results and modeling to predict outcomes in recipients with HCV infection: results of the NIDDK liver transplantation database. Liver Transpl 2004; 10:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/53\">",
"      Thuluvath PJ, Krok KL, Segev DL, Yoo HY. Trends in post-liver transplant survival in patients with hepatitis C between 1991 and 2001 in the United States. Liver Transpl 2007; 13:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/54\">",
"      Forman LM, Lewis JD, Berlin JA, et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/55\">",
"      Lai JC, Verna EC, Brown RS Jr, et al. Hepatitis C virus-infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men. Hepatology 2011; 54:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/56\">",
"      Nair S, Eustace J, Thuluvath PJ. Effect of race on outcome of orthotopic liver transplantation: a cohort study. Lancet 2002; 359:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/57\">",
"      Yilmaz N, Shiffman ML, Stravitz RT, et al. A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation. Liver Transpl 2007; 13:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/58\">",
"      Graziadei IW, Zoller HM, Schloegl A, et al. Early viral load and recipient interleukin-28B rs12979860 genotype are predictors of the progression of hepatitis C after liver transplantation. Liver Transpl 2012; 18:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/59\">",
"      Belli LS, Burroughs AK, Burra P, et al. Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study. Liver Transpl 2007; 13:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/60\">",
"      Berenguer M, Crippin J, Gish R, et al. A model to predict severe HCV-related disease following liver transplantation. Hepatology 2003; 38:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/61\">",
"      Neumann UP, Berg T, Bahra M, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004; 41:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/62\">",
"      Blasco A, Forns X, Carri&oacute;n JA, et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology 2006; 43:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/63\">",
"      Gawrieh S, Papouchado BG, Burgart LJ, et al. Early hepatic stellate cell activation predicts severe hepatitis C recurrence after liver transplantation. Liver Transpl 2005; 11:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/64\">",
"      Vargas HE, Laskus T, Wang LF, et al. Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts. Gastroenterology 1999; 117:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/65\">",
"      Velidedeoglu E, Desai NM, Campos L, et al. The outcome of liver grafts procured from hepatitis C-positive donors. Transplantation 2002; 73:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/66\">",
"      Lai JC, O'Leary JG, Trotter JF, et al. Risk of advanced fibrosis with grafts from hepatitis C antibody-positive donors: a multicenter cohort study. Liver Transpl 2012; 18:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/67\">",
"      Cimsit B, Schilsky M, Moini M, et al. Combined liver kidney transplantation: critical analysis of a single-center experience. Transplant Proc 2011; 43:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/68\">",
"      Van Wagner LB, Baker T, Ahya SN, et al. Outcomes of patients with hepatitis C undergoing simultaneous liver-kidney transplantation. J Hepatol 2009; 51:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/69\">",
"      Martin EF, Huang J, Xiang Q, et al. Recipient survival and graft survival are not diminished by simultaneous liver-kidney transplantation: an analysis of the united network for organ sharing database. Liver Transpl 2012; 18:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/70\">",
"      Carri&oacute;n JA, Fern&aacute;ndez-Varo G, Bruguera M, et al. Serum fibrosis markers identify patients with mild and progressive hepatitis C recurrence after liver transplantation. Gastroenterology 2010; 138:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/71\">",
"      Everson GT. Treatment of chronic hepatitis C in patients with decompensated cirrhosis. Rev Gastroenterol Disord 2004; 4 Suppl 1:S31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/72\">",
"      Everson GT, Trotter J, Forman L, et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005; 42:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/73\">",
"      Crippin JS, McCashland T, Terrault N, et al. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002; 8:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/74\">",
"      Everson GT, Terrault NA, Lok AS, et al. A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/75\">",
"      Gurusamy KS, Tsochatzis E, Xirouchakis E, et al. Antiviral therapy for recurrent liver graft infection with hepatitis C virus. Cochrane Database Syst Rev 2010; :CD006803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/76\">",
"      Bzowej N, Nelson DR, Terrault NA, et al. PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl 2011; 17:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/77\">",
"      Samonakis DN, Germani G, Burroughs AK. Immunosuppression and HCV recurrence after liver transplantation. J Hepatol 2012; 56:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/78\">",
"      Rabie R, Mumtaz K, Renner EL. Efficacy of antiviral therapy for hepatitis C after liver transplantation with cyclosporine and tacrolimus: a systematic review and meta-analysis. Liver Transpl 2013; 19:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/79\">",
"      F&eacute;ray C, Samuel D, Gigou M, et al. An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: antiviral effects and risk of rejection. Hepatology 1995; 22:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/80\">",
"      Wright TL, Combs C, Kim M, et al. Interferon-alpha therapy for hepatitis C virus infection after liver transplantation. Hepatology 1994; 20:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/81\">",
"      Gane EJ, Lo SK, Riordan SM, et al. A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation. Hepatology 1998; 27:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/82\">",
"      Cattral MS, Hemming AW, Wanless IR, et al. Outcome of long-term ribavirin therapy for recurrent hepatitis C after liver transplantation. Transplantation 1999; 67:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/83\">",
"      Gane EJ, Tibbs CJ, Ramage JK, et al. Ribavirin therapy for hepatitis C infection following liver transplantation. Transpl Int 1995; 8:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/84\">",
"      Toniutto P, Fabris C, Fumo E, et al. Pegylated versus standard interferon-alpha in antiviral regimens for post-transplant recurrent hepatitis C: Comparison of tolerability and efficacy. J Gastroenterol Hepatol 2005; 20:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/85\">",
"      Bizollon T, Palazzo U, Ducerf C, et al. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology 1997; 26:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/86\">",
"      Ahmad J, Dodson SF, Demetris AJ, et al. Recurrent hepatitis C after liver transplantation: a nonrandomized trial of interferon alfa alone versus interferon alfa and ribavirin. Liver Transpl 2001; 7:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/87\">",
"      Narayanan Menon KV, Poterucha JJ, El-Amin OM, et al. Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy. Liver Transpl 2002; 8:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/88\">",
"      Alberti AB, Belli LS, Airoldi A, et al. Combined therapy with interferon and low-dose ribavirin in posttransplantation recurrent hepatitis C: a pragmatic study. Liver Transpl 2001; 7:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/89\">",
"      Lavezzo B, Franchello A, Smedile A, et al. Treatment of recurrent hepatitis C in liver transplants: efficacy of a six versus a twelve month course of interferon alfa 2b with ribavirin. J Hepatol 2002; 37:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/90\">",
"      Firpi RJ, Abdelmalek MF, Soldevila-Pico C, et al. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transpl 2002; 8:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/91\">",
"      Shakil AO, McGuire B, Crippin J, et al. A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C. Hepatology 2002; 36:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/92\">",
"      Nair S, Khan S, Loss G, et al. Treatment of recurrent hepatitis C in liver transplant recipients: is there any histologic benefit? Liver Transpl 2003; 9:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/93\">",
"      Samuel D, Bizollon T, Feray C, et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003; 124:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/94\">",
"      Wang CS, Ko HH, Yoshida EM, et al. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant 2006; 6:1586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/95\">",
"      Gopal DV, Rosen HR. Duration of antiviral therapy for cholestatic HCV recurrence may need to be indefinite. Liver Transpl 2003; 9:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/96\">",
"      Beckebaum S, Cicinnati VR, Zhang X, et al. Combination therapy with peginterferon alpha-2B and ribavirin in liver transplant recipients with recurrent HCV infection: preliminary results of an open prospective study. Transplant Proc 2004; 36:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/97\">",
"      Castells L, Vargas V, Allende H, et al. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol 2005; 43:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/98\">",
"      Moreno Planas JM, Rubio Gonzalez E, Boullosa Gra&ntilde;a E, et al. Peginterferon and ribavirin in patients with HCV cirrhosis after liver transplantation. Transplant Proc 2005; 37:2207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/99\">",
"      Dumortier J, Scoazec JY, Chevallier P, Boillot O. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 2004; 40:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/100\">",
"      Rodriguez-Luna H, Khatib A, Sharma P, et al. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series. Transplantation 2004; 77:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/101\">",
"      Mukherjee S, Rogge J, Weaver L, Schafer DF. Pilot study of pegylated interferon alfa-2b and ribavirin for recurrent hepatitis C after liver transplantation. Transplant Proc 2003; 35:3042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/102\">",
"      Neff GW, Montalbano M, O'Brien CB, et al. Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy. Transplantation 2004; 78:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/103\">",
"      Babatin M, Schindel L, Burak KW. Pegylated-interferon alpha 2b and ribavirin for recurrent hepatitis C after liver transplantation: From a Canadian experience to recommendations for therapy. Can J Gastroenterol 2005; 19:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/104\">",
"      Oton E, Barcena R, Moreno-Planas JM, et al. Hepatitis C recurrence after liver transplantation: Viral and histologic response to full-dose PEG-interferon and ribavirin. Am J Transplant 2006; 6:2348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/105\">",
"      Neumann U, Puhl G, Bahra M, et al. Treatment of patients with recurrent hepatitis C after liver transplantation with peginterferon alfa-2B plus ribavirin. Transplantation 2006; 82:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/106\">",
"      Chalasani N, Manzarbeitia C, Ferenci P, et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology 2005; 41:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/107\">",
"      Angelico M, Petrolati A, Lionetti R, et al. A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. J Hepatol 2007; 46:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/108\">",
"      Saab S, Ly D, Han SB, et al. Is it cost-effective to treat recurrent hepatitis C infection in orthotopic liver transplantation patients? Liver Transpl 2002; 8:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/109\">",
"      Nair S, Lipscomb J, Eason J. Efficacy of interferon based antiviral therapy for recurrent hepatitis C in patients who received steroid free immunosuppression for liver transplantation. Transplantation 2008; 86:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/110\">",
"      Fukuhara T, Taketomi A, Motomura T, et al. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 2010; 139:1577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/111\">",
"      Charlton MR, Thompson AJ, Veldt BJ, et, al. IL28 polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with HCV infection. Hepatology 2010; 52:320A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/112\">",
"      Werner CR, Egetemeyr DP, Lauer UM, et al. Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data. Liver Transpl 2012; 18:1464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/113\">",
"      Garg V, van Heeswijk R, Lee JE, et al. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011; 54:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/114\">",
"      Neff GW, O'Brien CB, Nery J, et al. Factors that identify survival after liver retransplantation for allograft failure caused by recurrent hepatitis C infection. Liver Transpl 2004; 10:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/115\">",
"      Biggins SW, Beldecos A, Rabkin JM, Rosen HR. Retransplantation for hepatic allograft failure: prognostic modeling and ethical considerations. Liver Transpl 2002; 8:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/116\">",
"      Sheiner PA, Schluger LK, Emre S, et al. Retransplantation for recurrent hepatitis C. Liver Transpl Surg 1997; 3:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/117\">",
"      Rosen HR, O'Reilly PM, Shackleton CR, et al. Graft loss following liver transplantation in patients with chronic hepatitis C. Transplantation 1996; 62:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/118\">",
"      Berenguer M, Prieto M, Palau A, et al. Severe recurrent hepatitis C after liver retransplantation for hepatitis C virus-related graft cirrhosis. Liver Transpl 2003; 9:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/119\">",
"      Roayaie S, Schiano TD, Thung SN, et al. Results of retransplantation for recurrent hepatitis C. Hepatology 2003; 38:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/120\">",
"      Rosen HR, Prieto M, Casanovas-Taltavull T, et al. Validation and refinement of survival models for liver retransplantation. Hepatology 2003; 38:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/121\">",
"      Alamo JM, G&oacute;mez MA, Pareja F, et al. Morbidity and mortality in liver retransplantation. Transplant Proc 2006; 38:2475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/122\">",
"      Ercolani G, Grazi GL, Ravaioli M, et al. Histological recurrent hepatitis C after liver transplantation: Outcome and role of retransplantation. Liver Transpl 2006; 12:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/123\">",
"      McCashland T, Watt K, Lyden E, et al. Retransplantation for hepatitis C: results of a U.S. multicenter retransplant study. Liver Transpl 2007; 13:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/5/16474/abstract/124\">",
"      Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49:1335.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4583 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-180.241.123.62-6A9128D992-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_5_16474=[""].join("\n");
var outline_f16_5_16474=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Donor characteristics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Genotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Viral load",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H234608081\">",
"      Inflammatory grade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CD4 T-cell response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL COURSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Patterns of disease recurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Transplantation of HCV infected grafts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Combined liver-kidney transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PREVENTION OF RECURRENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TREATMENT OF RECURRENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Interferon monotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Ribavirin monotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Standard interferon plus ribavirin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Peginterferon monotherapy or combination therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Retransplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      AASLD GUIDELINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/4583\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4583|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/0/31755\" title=\"table 1\">",
"      Path features HCV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/30/11744\" title=\"table 2\">",
"      Telaprevir drug interactions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31530?source=related_link\">",
"      Clinical manifestations and natural history of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31289?source=related_link\">",
"      Hepatitis C virus infection and renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/30/39398?source=related_link\">",
"      Histologic scoring systems for chronic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38378?source=related_link\">",
"      Investigational therapies for hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/32/36362?source=related_link\">",
"      Liver transplantation for hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28184?source=related_link\">",
"      Mechanism of action and efficacy of ribavirin for the treatment of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/12/30922?source=related_link\">",
"      Overview of immunosuppression in adult liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/45/43735?source=related_link\">",
"      Overview of the management of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/61/25559?source=related_link\">",
"      Patient selection for liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41849?source=related_link\">",
"      Screening for and diagnosis of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/26/15785?source=related_link\">",
"      Studies of telaprevir and boceprevir in the treatment of chronic hepatitis C virus genotype 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24314?source=related_link\">",
"      Treatment regimens for chronic hepatitis C virus genotype 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/37/600?source=related_link\">",
"      Treatment regimens for chronic hepatitis C virus genotypes 2, 3, and 4",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_5_16475="Cardiac defects causing hydrops";
var content_f16_5_16475=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F77350&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F77350&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Structural cardiac abnormalities associated with hydrops fetalis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Ventricular hypoplasia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cardiomyopathy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Aortic or pulmonary stenosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Valvular insufficiency",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Single ventricle",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Atrial or ventricular septal defect",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Closure of the foramen ovale",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Transposition of the great arteries",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tetralogy of Fallot",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ebstein's anomaly",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Truncus arteriosus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Rhabdomyoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Premature closure of the ductus arteriosus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cardiosplenic syndromes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Endocardial fibroelastosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_5_16475=[""].join("\n");
var outline_f16_5_16475=null;
var title_f16_5_16476="ACC AHA Rx cardiogenic shock";
var content_f16_5_16476=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F54567&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F54567&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA/ESC guideline summary: Treatment of cardiogenic shock in patients with acute myocarial infarction (MI)*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I - There is evidence and/or general agreement that the following approaches are indicated in the treatment of cardiogenic shock in patients with an acute MI:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Intraaortic balloon counterpulsation when cardiogenic shock is not quickly reversed with pharmacologic therapy. The IABP is a stabilizing measure for angiography and prompt revascularization.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Intraarterial monitoring.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Early revascularization with either PCI or CABG for patients less than 75 years of age who develop shock within 36 hours of MI and who are suitable for revascularization that can be performed within 18 hours of shock. This recommendation does not apply when further support is futile because of the patient's wishes or contraindications to or unsuitability for further invasive care.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Among patients with ST elevation MI, fibrinolytic therapy in those who are not suitable for revascularization and have no contraindications to fibrinolysis.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Unless assessed by invasive testing, echocardiography to evaluate for possible mechanical complications.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIa - The weight of evidence or opinion is in favor of the usefulness of the following approaches in the treatment of cardiogenic shock in patients with an acute MI:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Pulmonary artery catheterization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Early revascularization with either PCI or CABG for selected patients 75 years of age or older (eg, patients with good functional status who agree to invasive care) who develop shock within 36 hours of MI and who are suitable for revascularization that can be performed within 18 hours of shock.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * These guidelines were for patients with ST elevation MI or MI associated with left bundle branch block. Similar principles apply to cardiogenic shock developing in patients with a non-ST elevation MI.",
"    </div>",
"    <div class=\"reference\">",
"     Data from Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004; 110:588.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_5_16476=[""].join("\n");
var outline_f16_5_16476=null;
var title_f16_5_16477="Tissue stains for endoscopy";
var content_f16_5_16477=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F68885&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F68885&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Tissue stains used during gastrointestinal endoscopy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Stain type",
"       </td>",
"       <td class=\"subtitle1\">",
"        What is stained",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mechanism of staining",
"       </td>",
"       <td class=\"subtitle1\">",
"        Positive staining",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical uses in GI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Vital stains",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Lugol's solution (iodine + potassium iodide)",
"       </td>",
"       <td rowspan=\"3\">",
"        Normal glycogen containing squamous cells",
"       </td>",
"       <td rowspan=\"3\">",
"        Binds iodine in non-keratinized cells",
"       </td>",
"       <td rowspan=\"3\">",
"        Dark brown",
"       </td>",
"       <td>",
"        1) Squamous cell esophageal cancer (non-staining)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2) Columnar epithelium in the esophagus, including residual Barrett's esophagus following mucosal ablation (non-staining)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3) Reflux esophagitis (non-staining)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"5\">",
"        Methylene blue (methylthionine chloride)",
"       </td>",
"       <td rowspan=\"5\">",
"        Small or large intestinal cells or intestinal metaplasia",
"       </td>",
"       <td rowspan=\"5\">",
"        Active absorption into cells",
"       </td>",
"       <td rowspan=\"5\">",
"        Blue",
"       </td>",
"       <td>",
"        1) Specialized epithelium (intestinal metaplasia) in Barrett's esophagus*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2) Intestinal metaplasia in the stomach",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3) Early gastric cancer&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4) Gastric metaplasia in the duodenum (non-staining)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5) Celiac and tropical sprue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Toluidine blue (tolonium chloride or dimethylamino-toluphenazothioni-chloride)",
"       </td>",
"       <td rowspan=\"2\">",
"        Nuclei of columnar (gastric and intestinal-type) cells",
"       </td>",
"       <td rowspan=\"2\">",
"        Diffuses into cell",
"       </td>",
"       <td rowspan=\"2\">",
"        Blue",
"       </td>",
"       <td>",
"        1) Squamous cell carcinoma of the esophagus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2) Gastric or intestinal metaplasia in Barrett's esophagus",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Reactive stains",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Congo red (biphenylene-napthadene sulfornic acid)",
"       </td>",
"       <td rowspan=\"2\">",
"        Acid-containing gastric cells",
"       </td>",
"       <td rowspan=\"2\">",
"        Acid pH &lt;3.0 results in color change",
"       </td>",
"       <td rowspan=\"2\">",
"        Turns red to dark blue or black",
"       </td>",
"       <td>",
"        1) Acid-secreting gastric mucosa (including ectopic locations)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2) Gastric cancer (nonstaining); (may be combined with methylene blue to outline intestinal metaplasia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Phenol red (phenolsulfonphthalein)",
"       </td>",
"       <td>",
"        H. pylori-infected gastric cells",
"       </td>",
"       <td>",
"        Alkaline pH (from hydrolysis of urea to NH3 and CO2 by urease) results in color change",
"       </td>",
"       <td>",
"        Turns yellow to red",
"       </td>",
"       <td>",
"        Diagnose Helicobacter pylori infection (positive color change) and map its distribution in the stomach",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Contrast stain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Indigo carmine&Delta;",
"       </td>",
"       <td rowspan=\"2\">",
"        Cells are not stained",
"       </td>",
"       <td rowspan=\"2\">",
"        Pools in crevices and valleys between mucosal projections",
"       </td>",
"       <td rowspan=\"2\">",
"        Blue (indigo)",
"       </td>",
"       <td>",
"        1) Colon, gastric, duodenal, esophageal lesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2) Barrett's esophagus",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Methylene blue does not stain non-specialized or gastric metaplasia; specialized columnar epithelium stains blue, but highly dysplastic or malignant specialized columnar epithelium in Barrett's esophagus generally takes up little to no dye; low grade dysplasia in Barrett's esophagus may or may not take up stain.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      With or without Congo red.",
"      <br>",
"       &Delta; Also used in combination with high resolution or high magnification endoscopy; may be used with or without crystal violet (for early colorectal cancers).",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Canto M. Staining in Gastrointestinal Endoscopy: The Basics. Endoscopy 1999; 31:479. Copyright &copy; 1999 Thieme Medical Publishers, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_5_16477=[""].join("\n");
var outline_f16_5_16477=null;
var title_f16_5_16478="Distal fibular fracture adult";
var content_f16_5_16478=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F55491&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F55491&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Distal fibula fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 217px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This anteroposterior radiograph shows a fracture of the distal fibula.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Karl B Fields, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_5_16478=[""].join("\n");
var outline_f16_5_16478=null;
var title_f16_5_16479="Loopmarks scar";
var content_f16_5_16479=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F79721&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F79721&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Loopmarks scar",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 190px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Stephen Ludwig, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_5_16479=[""].join("\n");
var outline_f16_5_16479=null;
